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EphA2, also known as ECK (epithelial cell kinase), is a transmembrane receptor 
tyrosine kinase that is commonly over-expressed in cancers such as those of the prostate, 
colon, lung, and breast. For breast cancers, EphA2 overexpression is most prominent in 
the ER-negative subtype, and is associated with a higher rate of lung metastasis. Studies 
conducted to demonstrate the role of EphA2 in a non-cancerous environment have shown 
that it is very important in developmental processes, but not in normal adult tissues. 
These results make EphA2 a prospective therapeutic target since new therapies are 
needed for the more aggressive ER-negative breast cancers. A panel of breast cancer cell 
lines was screened for expression of EphA2 by immunoblotting. Several of the 
overexpressing cell lines, including BT549, MDA-MB-231, and HCC 1954 were selected 
for experiments utilizing siRNA for transient knockdown and shRNA for stable 
knockdown. Targeted knockdown of EphA2 was measured using RT-PCR and 
immunoblotting techniques.  
Here, the functions of EphA2 in the process of metastasis have been elucidated 
using in vitro assays that indicate cancer cell metastatic potential and in vivo studies that 
reveal the effect of EphA2 on mammary fat pad tumor growth, vessel formation, and the 
effect of using EphA2-targeting siRNA on pre-established mammary fat pad tumors. A 
decrease in EphA2 expression both in vitro and in vivo correlated with reduced migration 
and experimental metastasis of breast cancer cells. Current work is being done to 
investigate the mechanism behind EphA2’s participation in some of these processes. 
These studies are important because they have contributed to understanding the role that 
EphA2 plays in the progression of breast cancers to a metastatic state.  
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Introduction 
Cancer has continuously been a significant source of health concern in countries 
all over the world (1). It is the second leading cause of death in the United States, lagging 
only behind heart disease (1). While there are many types of cancer, breast cancer is one 
of particular interest due to the fact that there will be an estimated 209,060 new cases and 
40,230 deaths attributed to this disease in 2010 alone (1). In women, it is the most 
commonly diagnosed cancer and is the second leading cause of cancer-related deaths (1). 
Furthermore, the disparity between the number of new diagnoses and annual deaths 
corroborate established findings that breast cancers are considerably variable and may or 
may not lead to lethality (2). Disease dissemination to distant sites within the body, a 
process called metastasis, is the major contributor to high breast cancer mortality rates 
(3). Overcoming the limitations in our understanding of metastasis and breast cancer 
biology requires further research and investigation so that new treatments may be 
developed and current therapies may be improved (2).  
 
Understanding the Anatomy of the Breast 
 It is important to begin with a foundation in basic breast anatomy and function in 
order to understand the role that these anatomical features and processes play in the 
development and progression of breast cancers.  
 Mammary glands are a unique feature of mammals that function to secrete milk as 
a means of providing nourishment and transferring passive immunity to newborn 
organisms (4). In humans, the mature female breast consists of approximately 15-20 
lobes that radiate outward from the nipple (4) (Figure 1). These lobes are composed of 
smaller structures, called lobules (4). Acini are the hollow, sac-like constituents of the 
lobules that are responsible for producing and storing milk during pregnancy (4, 5). 
Tubular structures, called ducts, form a network of branched passages that initiate at the 
lobules and ultimately converge to provide a single route to the exterior through the 
nipple (4). The remainder of the breast is composed of adipose tissue and connective 
tissue infiltrated with lymph and blood vessels (5).  
 At the cellular level, both the lobules and the ducts are composed of an inner 
luminal epithelial cell layer and outer myoepithelial cell layer (6) (Figure 2). The 
myoepithelial cells, also called basal cells, are then followed by a lining of basement 
membrane (6, 7). The ductal myoepithelial cells differ from the acinar myoepithelial cells 
in that they are layered continuously around the luminal cells, whereas acinar 
myoepithelial cells are discontinuously layered (6). While there are many factors that 
play a role in characterizing breast cancers, the luminal or basal-like gene expression 
patterns seen in various tumor samples has led to the classification of subtypes of breast 
cancers and has helped to create a basic level of organization within this otherwise 
heterogeneous disease (8).  
  
 
 
 
 
 
 
  
 
Figure 1 
Basic Breast Anatomy 
 
Reference (9) 
Permission to Use Figure Granted by National Cancer Institute 
 
 
 
 
 
  
Figure 2 
Cellular Components of the Breast Ducts and Lobules 
 
Reference (6) 
Permission to Use Figure Granted by Original Publisher, BioMed Central 
 
 
 
Predisposition and Risk Factors 
 Breast cancer may affect any person, but there are certain well-known factors that 
indicate a higher likeliness for disease development in select individuals (10). The most 
defining risk factors are age and sex (11). While men can be afflicted with this disease, 
the number of diagnoses and deaths in men are significantly fewer than in women and the 
majority of women diagnosed are normally 50 years of age or older (10, 11). Other 
factors that potentiate an increased risk include, but are not limited to, early onset of 
menstruation or late onset of menopause, obesity, becoming pregnant at an older age, 
familial history of breast cancer, and inheritance of genetic alterations (11). Mutations in 
either of the two genes, BRCA1 and BRCA2, are known for heightening the risk of 
breast cancer development and are found in 5-10% of patient cases (12). Furthermore, 
TP53 and PTEN are examples of two other genes that may harbor mutations and 
inheritance of these altered copies increases an individual’s risk of disease development 
(13).   
 
Types of Breast Cancer 
 As aforementioned, breast cancer is a diverse disease originating from a genetic 
predisposition or accumulation of spontaneous somatic mutations over time (18). 
However, not all breast disorders are considered to be cancerous and many non-
cancerous conditions do not share the same projected risk of maturing into malignant 
disease (14).  
Benign breast lesion is a term that collectively describes abnormalities of the 
breast that have varying risks for developing cancer, however, this risk may be higher or 
lower depending on the specific condition (14). Examples of irregularities that are 
considered to have no associated risk of breast cancer development include lipomas, 
mastitis, and lymphadenitis (14). On the other hand, atypical ductal and lobular 
hyperplasia represent benign lesions that confer a higher potential to become malignant 
(14). Despite the disparity between these conditions and their associated cancer 
development risk, benign breast lesions are not contributors to breast cancer mortality 
rates and, if treated early, will not develop into a malignancy (14). 
 However, if left untreated, atypical ductal and lobular hyperplasia may lead to 
ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS), respectively (15). 
DCIS and LCIS are considered to be intermediary lesions that are precursors to invasive 
cancers (15, 16). DCIS is the more common form of in situ breast cancer and has a higher 
tendency to become invasive (15). Invasive forms of the disease have penetrated the 
basement membrane and infiltrated the surrounding tissue (15). Approximately 80% of 
breast cancer patients have invasive ductal carcinoma (IDC), whereas only 10% have 
invasive lobular carcinoma (ILC), also called infiltrating lobular carcinoma (15). Cancer 
cells constituting an invasive carcinoma have the potential to spread to regional lymph 
nodes and blood vessels where they will be disseminated throughout the body and could 
create tumors at distant sites (15). 
 A less commonly diagnosed type of breast cancer is called inflammatory breast 
cancer. Affecting less than 5% of all breast cancer patients, this form of the disease is not 
associated with the development of a lump in the breast (17). Rather, its symptoms 
include redness, swelling, and inflammation as a result of lymph vessel blockage by 
cancer cells and is often misdiagnosed (17). This rare disease is aggressive, highly 
metastatic, and has a 5 year survival rate of less than 5% (17).  
 
Heterogeneity within Breast Cancers Creates Subtypes  
 Transcriptional profile analysis and subsequent hierarchical clustering of data 
from a variety of breast tumor samples and breast cancer cells lines have revealed 
subtypes with specific genetic expression patterns (8, 13, 18). These subtypes include the 
luminal A and B, HER2-overexpressing (Human Epidermal Growth Factor Receptor 2), 
normal-like, and basal-like breast cancers (13). Each subtype is associated with a distinct 
prognosis and subsequent clinical outcome that makes identification of each patient 
tumor subtype both necessary and relevant (19). 
 Luminal breast cancers makeup approximately 45% of all breast cancers and are 
most likely to be low grade and differentiated (20). Identification of luminal tumors is 
carried out by staining for keratins 8/18, which are known to be expressed in normal 
luminal cells (18). Additionally, these tumor types express the estrogen (ER) and 
progesterone (PR) receptors and while luminal tumors are generally positive for these 
hormone receptors, variation in their expression leads to the classification of the luminal 
A and B groups (8, 13). Several genes, known to encode transcription factors that interact 
with ER, are upregulated in luminal-type breast cancers (20). These genes include 
FOXA1, GATA3, and PAX2, among others (18, 20). Some of these transcription factors 
serve as the driving forces behind luminal breast cancer proliferation and survival (20, 
21). Despite intergroup heterogeneity, luminal tumors are clinically more easily treatable 
than HER2 or basal-like tumors and are generally associated with a good prognosis (22).    
 HER2/neu is overexpressed in 25% of all breast cancers as a result of 
amplification of the ERBB2 gene (18, 23). HER2-overexpressing tumors express ER to a 
lesser degree than luminal tumors (18). In fact, these tumors are more similar to basal-
like tumors in that they lack expression or upregulation of those genes known to 
characterize ER positive tumors (18). HER2 overexpression is associated with tumors 
that are less differentiated and have a higher extent of proliferation, invasion, and 
metastasis (24). Clinically, HER2 overexpression correlates with a poorer prognosis and 
increased mortality rate in comparison to luminal tumors (25). 
 Finally, the basal-like breast cancers represent about 15% of all breast cancer 
cases and are identified by staining for keratins 5/6 or 17 (18, 19, 26). While most of 
these tumors share histological features, they are difficult to define universally due to the 
lack of common morphological features used during diagnosis (19, 20). As the name 
suggests, basal-like carcinomas express gene patterns analogous to those seen in the 
normal basal, or myoepithelial cells, of the breast (13, 26). Notably, basal breast cancers 
are associated with the “triple-negative” phenotype, meaning they lack ER and PR, and 
may exhibit little or no expression of the HER2 growth factor receptor (8). Interestingly, 
basal carcinomas have also been associated with the CD44+/CD24-/low expression pattern 
and this is virtually unseen in the other subtypes (27). CD44+/CD24-/low cell populations 
have been linked to being less differentiated and having higher invasive capabilities, a 
property that reflects the poor patient outcome seen in the clinic (19, 27). Basal-like 
breast cancers generally develop in patients at a younger age, are aggressive, are likely to 
metastasize, have a poor prognosis, and are characterized by a high mortality rate (26).  
 
Breast Cancer Staging 
 Patients who have breast cancer are diagnosed at various points during disease 
progression. Cancer staging has evolved as a way to convey the extent and severity of a 
patient’s disease by describing the basic primary tumor characteristics and degree of 
spread from the original site, if any (9). Breast cancer staging is useful for clinicians 
because it provides them with a common terminology when referring to patient disease 
status (9). Furthermore, it provides a useful way to approximate prognosis, employ 
treatment strategies, and monitor disease progression (28).  
 During the mid 20th century, a detailed system of staging, termed the TNM 
staging system, was developed (28). This system describes those characteristics of cancer 
that are thought to most influence prognosis including tumor size, node involvement, and 
identification of metastases (tumor-node-metastasis) (28). The American Joint 
Committee on Cancer, AJCC, has since produced a TNM staging of breast cancer that 
has undergone constant revisions to reflect the updates in our knowledge of disease 
progression (28). The most current TNM staging utilizes clinical, pathological, 
recurrence, and autopsy classifications to obtain the most accurate and descriptive stage 
of a patient’s disease (9, 28) (Table 1).  
 
 
 
 
 
 
 Table 1  
Basic Breast Cancer Stages  
Stage Sub-Stage Description 
I A Tumor ≤ 2cm, no spread 
 B - No tumor in breast, but cancer cells in 
lymph nodes 
- Tumor ≤ 2cm and cancer cell clusters in 
lymph nodes 
II A - No tumor in breast, cancer in axillary 
lymph nodes 
- Tumor ≤ 2cm, axillary lymph node 
spread 
- 5cm ≥ Tumor ≥ 2cm, no axillary lymph 
node spread 
 B - 5cm ≥ Tumor ≥ 2cm, axillary lymph 
node spread 
- Tumor ≥ 5cm, no axillary lymph node 
spread 
III A - No tumor in breast, cancer in axillary 
lymph nodes or in lymph nodes near 
breastbone 
- Tumor ≤ 2cm, cancer in axillary lymph 
nodes or in lymph nodes near breastbone 
- 5cm ≥ Tumor ≥ 2cm, cancer in axillary 
lymph nodes or in lymph nodes near 
breastbone 
- Tumor ≥ 5cm, cancer in axillary lymph 
nodes or in lymph nodes near breastbone 
 B - Tumor any size, spread to chest wall 
and/or skin 
- Possible spread to axillary lymph nodes 
or lymph nodes near the breastbone 
 C No sign of cancer or tumor of any size 
that may have spread to chest wall and/or 
skin: 
- Possible spread to lymph 
nodes near collar bone 
- Possible spread to axillary 
lymph nodes or lymph nodes 
near breastbone 
  
Operable: Cancer found in 10+ axillary 
lymph nodes, in lymph nodes below 
collarbone, in axillary lymph nodes and in 
lymph nodes near the breastbone 
  
Inoperable: Cancer has spread to the 
lymph nodes above the collarbone 
IV  Cancer has spread to other organs, most commonly the bones, lungs, liver, or 
brain. 
 
Reference (9) 
 
 Treatment Strategies 
 The therapeutic significance of the heterogeneous nature of breast cancer is that 
each patient case must be assessed individually and a therapy regiment should be 
designed based on the results of that assessment (29).  Therapeutic decisions rely heavily 
on proper staging and analysis of a patient’s disease (30). 
 Surgery is often the standard mode of treatment for patients with in situ 
carcinomas or very early stage invasive carcinomas (30). Radical mastectomies have 
been replaced by two types of breast-conserving surgeries (30). First, patients with small, 
non-invasive or early stage invasive breast cancers may undergo lumpectomy followed 
by radiation therapy (30, 31). Second, in the case of patients who have larger primary 
tumors and local advancement of their disease, chemotherapy administration prior to 
surgery, also known as neoadjuvant therapy,  has proved to benefit some patients by 
causing tumor shrinkage and facilitating its removal (30). Furthermore, the newly 
developed method of sentinel lymph node mapping, whereby a blue dye is administered 
to the surrounding area of a tumor, has reduced the need for axillary lymph node 
dissections because the histological state of the sentinel lymph nodes is highly predictive 
of the state of the axillary lymph nodes (32). Disease-free sentinel lymph nodes spare the 
removal of the axillary lymph nodes which is associated with increased patient morbidity 
(32). 
  In contrast to taking a surgical approach, primary tumors may also be 
treated systemically with hormonal agents, various combinations of chemotherapies, or 
both (31). The treatment that is administered depends on the hormone receptor status of 
the tumor, identifying markers, and the extent of the disease (30-32). Examples of agents 
used in the treatment of ER and PR positive breast cancers include tamoxifen, 
toremifene, fulvestrant, and progestins (30). For patients with a receptor positive status, 
these hormone therapies may be used in combination with other chemotherapies (30). 
Targeted therapy also exists for patients with HER2 overexpression including, but not 
limited to, trastuzumab and lapatinib (25). Trastuzumab may also be used for patients 
with hormone positive disease (30). Those patients whose breast cancer is characterized 
as triple-negative are harder to treat because the pathways that drive tumor growth under 
these conditions haven’t been fully elucidated (33). Treatment is varied and often 
includes the use of platinum-based drugs, taxanes, cetuximab, imatinib, pertuzumab, and 
others (33). Chemotherapy is generally the primary therapy administered, but it can also 
be used in combination with radiotherapy, and again, the decision to utilize this mode of 
treatment is dependent on the characteristics of the patient’s disease (31). 
 If a patient’s disease is determined to be metastatic at the time of diagnosis, 
surgery is usually not the primary choice of therapy because the cancer has already 
spread and cannot be contained by removal of the tumor, although it can be beneficial in 
rare cases (32). At this point, it is important to identify the number and locations of the 
metastases in order to develop an appropriate therapeutic protocol (32). Breast cancer 
preferentially metastasizes to the lungs, bone, brain, and liver (32). Metastatic patients 
receive several chemotherapeutic and occasionally hormonal agents in addition to 
radiotherapy, but often their disease becomes resistant to the available therapies and the 
patient ultimately succumbs to their cancer (32, 33).  Most metastatic breast cancer cases 
are triple-negative (33). As aforementioned, there currently isn’t a recommended 
systemic treatment regimen specific for triple-negative cancers (33). Therefore, there is 
motivation to find molecular therapeutic targets that are necessary and sufficient for 
progression of the cancer to the malignant state in order to broaden the treatment options 
available to these patients (33). 
 
Introduction to the Eph Subfamily and EphA2 
 EphA2 is a member of the largest subfamily of receptor tyrosine kinases (RTKs), 
the Eph subfamily (34). EphA1, the first receptor in the Eph subfamily to be discovered, 
was identified in 1987 by Hirai et al (35). To date, there are fourteen total members that 
are further subdivided into the EphA and EphB subgroups based on sequence homology 
(36). The EphA subgroup has nine members, EphA1-8, and the EphB subgroup has five 
members, EphB1-6 (36).  
Eph receptors bind membrane-bound ligands on adjacent cells, called ephrins, that 
are also subdivided into the A and B groups based on the receptor they bind (37). There 
are five A-ephrin ligands that are anchored to the cell membrane by a 
glycophosphatidylinositol (GPI) linkage (37). In contrast, the B-ephrins are 
transmembrane ligands consisting of only three total members (37). In general, EphA 
receptors preferentially bind A-ephrins, while EphB receptors preferentially bind B-
ephrins, although there is some binding promiscuity seen between receptors and ligands 
of opposing groups (38). Despite this, all ephrin-Eph receptor binding leads to receptor 
autophosphorylation and subsequent activation (34, 39).  
Ephrin-Eph receptor interactions have been linked to several functions, mostly in 
the developing nervous system where they are involved in axon guidance, cell migration, 
synaptic plasticity, and boundary maintenance (38, 39). Furthermore, there are also 
implications of Eph-ephrin involvement outside of the nervous system such as during 
vascular development (39, 40). While their functions are numerous and diverse, studying 
the effect of Eph-ephrin signaling has been difficult due to the functional compensatory 
ability of the receptor-ligand complexes (39).  
 Located on chromosome 1p36.1, EphA2 is a 130 kDa receptor tyrosine kinase 
that was discovered in 1990 and was originally named eck, epithelial cell kinase, because 
of the abundance of its mRNA and protein expression in epithelial cells (41, 42). The 
entire EphA2 gene consists of an open reading frame flanked by either a 5’ or 3’ 
untranslated region (41). The open reading frame encodes for 976 amino acids and the 5’ 
and 3’ regions are composed of 113 and 925 nucleotides, respectively (41). Original eck 
expression analysis revealed that those tissues with the highest levels of EphA2 include 
the skin, ovary, small intestine, and lung (41). Subsequent studies have revealed the 
expression and importance of EphA2 function in the breast (43).  
Extracellularly, the EphA2 receptor is composed of a NH2-terminal ligand-
binding domain, cysteine-rich domain, and two fibronectin-type III repeats (44). The 
intracellular domain begins with a juxtamembrane domain (44). This domain has two 
tyrosines that can carry out autophosphorylation (44). Next there is a tyrosine kinase 
domain, sterile α motife (SAM), and PDZ domain-binding motif (44). The latter two, 
located at the COOH-terminal end, interact with proteins that can initiate downstream 
signaling such as the src-like adapter protein (SLAP), c-cbl, p85 subunit of 
phosphoinositide 3-kinase (PI3K), src-homology domain-containing (SHC) protein, SH2 
domain-containing tyrosine phosphatase 2 (SHP2), and focal adhesion kinase (FAK) (34, 
44, 45) (Figure 3).  
  
Figure 3 
Structure of Eph Receptors and Ephrin Ligands 
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EphA2, like its family members, also participates in embryonic development of 
the central nervous and vascular system (47). Specifically, it has been identified to be 
important in pattern formation, a process that occurs during gastrulation to ensure correct 
cell differentiation and growth within the embryo, as well as with proper development of 
various tissues within the fetus (48). Additionally, EphA2 is important in correct 
placental development during the first trimester of pregnancy (49).  
In addition to its expression and involvement in prenatal functions, EphA2 also 
plays a crucial role in the young adult and adult organism, where its expression is limited 
to proliferating epithelial cells (43, 50). Mammary branching morphogenesis is a 
complex process that occurs in the breast shortly after the onset of puberty whereby the 
branched ductal network is established (43, 51). EphA2 was found to be the only Eph 
family receptor expressed in the terminal end buds, structures known to initiate the 
branching process in the breast (43, 51). Post puberty, the expression of EphA2 is 
upregulated during the pre-estrous and estrous phases of the estrous cycle (50, 52). 
Importantly, EphA2 expression is significantly decreased in differentiated mammary 
epithelium (53). This unique expression of EphA2 in the breast and its overexpression in 
highly aggressive breast cancers is one of many reasons why this receptor tyrosine kinase 
has been a protein of research interest and investigation (53, 54).  
 
EphrinA1 Ligand –EphA2 Receptor Interactions 
 Ephrin ligands and Eph receptors have a unique relationship in regards to their 
interaction and function in normal versus cancerous cells. As previously mentioned, 
ephrinA ligands preferentially bind EphA receptors, and the same can be said for B 
ligands and receptors (44). This is due to the specific amino acids found in the G-H loop 
of ephrins, the location where receptor and ligand binding is thought to occur (44). Slight 
differences in the amino acid sequence unique to certain members of the A or B 
receptors, such as the EphA4 receptor, are responsible for the promiscuity of binding 
between the A and B groups (44).  
 It is important to remember that both the ephrin ligands and the Eph receptors are 
membrane bound (34).  Therefore, cell-cell contact is necessary for any ligand to interact 
with its receptor (34). An ephrin ligand will bind its receptor through a high-affinity 
interface which subsequently causes a lower-affinity interface to be exposed (34, 55). 
This lower-affinity interface allows for tetramerization of two ephrin-Eph complexes (34, 
55). Transphosphorylation of the cytoplasmic portion of an Eph receptor occurs on the 
tyrosine residues in the juxtamembrane region, releasing the inhibition of the kinase 
domain and allowing for receptor activation (34, 55).  
 One of the more interesting features of the EphA2 receptor is its participation in 
both tumor suppressive and tumor promoting functions (50, 56). In breast cancer, 
EphA2’s tumor promoting abilities are associated with being unbound to ligand, whereas 
its tumor suppressive functions result from ligand activation of the receptor (56). This 
further translates into differences in the tyrosine phosphorylation state of the EphA2 
receptor (56). Ligand stimulation causes receptor phosphorylation that initiates a variety 
of downstream activities that negatively regulate migration, invasion, and growth in non-
transformed epithelial cells (56). For example, when activated by ligand, EphA2 will 
interact with molecules like the SHC protein, GRB2 (Growth Factor Receptor Bound 
Protein 2), SLAP, and will initiate PI3K activity (45, 57, 58). This is to be contrasted 
with the cancerous state, where EphA2 is not ligand activated and therefore exhibits 
significantly reduced tyrosine phosphorylation at sites that would normally be 
phosphorylated in response to ligand stimulation (56). Despite this lack of receptor 
stimulation by ligand, EphA2 maintains its enzymatic activity (56, 59). The downstream 
pathways initiated by EphA2 in its non-ligand bound state are distinct from its ligand-
activated state and result in the promotion of migration, invasion, and growth (53, 56, 
59). For example, EphA2 has been reported to interact with FAK and E-Cadherin 
independent of ligand activation (60). Loss of E-cadherin disrupts ligand-receptor 
binding and increases EphA2 association with FAK, ultimately leading to increased ECM 
interactions (59, 60). 
 In summary, the disparity in tyrosine phosphorylation in non-neoplastic and 
metastatic cells has important downstream signaling consequences that result in either the 
maintenance of a homeostatic state or promotion of cancer progression. These 
consequences have not been fully explored, but further study and enhanced understanding 
of them would allow for better therapies to be developed for EphA2 overexpressing 
breast cancers.  
 
The Role of EphA2 in Cancer 
 In addition to the many functions of EphA2 in the normal processes of 
embryogenesis and in adult epithelial tissues, overexpression of EphA2 has been found in 
a variety of aggressive tumor types and is sufficient to drive malignant transformation in 
non-transformed cell lines in vitro (53, 61, 62).  
 Zeng et al. sought to look at EphA2 levels in both cancerous and benign prostate 
samples (63). Immunohistochemical analysis revealed high intensity EphA2 staining in 
both high-grade intraepithelial neoplasia and adenocarcinomas of the prostate (63). 
Conversely, adjacent benign tissue from the same samples showed significantly weaker 
staining patterns for EphA2, easily differentiating the neoplastic regions from the normal 
regions (63). This study was particularly significant because the expression of EphA2 in 
high-grade neoplastic prostatic epithelial cells, a pre-malignant condition, implies that 
EphA2 is involved in the early stages of disease progression (63). 
 EphA2 involvement has also been implicated in pancreatic cancer, the fourth 
deadliest cancer in the United States (64). Overexpression of EphA2 in the Capan2 
pancreatic cell line, a cell line that is poorly metastatic in vivo with low natural levels of 
EphA2, conferred an increase in invasive capability in vitro and increased resistance to 
anoikis (64). Furthermore, EphA2 siRNA was used to suppress EphA2 overexpression in 
the more aggressive PANC1 and MIAPaCa2 cell lines (64). This resulted in a decrease in 
FAK phosphorylation, a molecule whose activation is important in EphA2-mediated 
interactions with the extracellular matrix (ECM) during cancer progression (64). 
 Additionally, EphA2 is commonly overexpressed in ovarian cancer (65). This 
overexpression is related to more severe forms of the disease and is associated with poor 
patient outcome (65).  It has been revealed that a possible reason for this negative 
outcome in EphA2 overexpressing ovarian cancer patients is due to the involvement of 
the receptor in the process of angiogenesis (66). Angiogenesis is one of the hallmarks of 
cancer that is largely responsible for tumor sustenance and growth (66, 67). Targeting 
EphA2 in ovarian cancer has been the subject of much investigation (66).   
 Prostate, ovarian, and pancreatic cancer are only a few examples where EphA2 
overexpression is known to play a role in tumor promotion and aggressive behavior (63, 
65, 66). Others include esophageal cancer, melanomas, colorectal cancer, cervical cancer, 
renal cancer, and non-small cell lung cancer (68-73). 
 
  
Regulation of EphA2 
 Due to the association of EphA2 with wide-spread involvement in the most 
aggressive cancers, there has been interest in elucidating the mechanisms that regulate it 
in a normal environment. Cancer-causing mutations result in the disruption of molecular 
regulatory pathways that are necessary for normal cell function and homeostasis (67). 
The unveiling of regulatory mechanisms that influence EphA2 expression has provided 
insight into how this protein becomes overexpressed in breast cancer and has opened the 
door for investigation of the effects of this aberrant upregulation.      
 
Estrogen & c-myc 
 As previously mentioned, a large majority of the most aggressive breast cancers 
do not express the estrogen receptor (8, 74). Furthermore, EphA2 is largely 
overexpressed in aggressive and ER negative cell lines (53). Zelinski et al confirmed that 
there is an inverse relationship governing ER and EphA2 expression at the protein level 
(75). This observation led to the hypothesis that estrogen is responsible for the negative 
regulation of EphA2 expression (75). Indeed, multiple non-transformed mammary 
epithelial cell lines were used to show a dose-dependent decrease in the protein levels of 
EphA2 (75). Furthermore, estradiol treatment of cell lines deficient in ER expression had 
no effect on EphA2 expression (75). An interesting finding in this investigation was that 
two transformed cell lines had limited expression of both ER and EphA2 (75). 
Ultimately, it was discovered that independently high levels of c-myc, a gene target of 
estrogen, could also cause inhibition of EphA2 expression (75, 76). Taken together, these 
results suggest that as breast cancer progresses towards malignancy, ER expression is lost 
and this releases EphA2 from the inhibitory effects of estrogen, allowing it to become 
overexpressed on the cell membrane (75, 76).   
 
Ras 
 Furthermore, Macrae et al have shown that stimulation of the Ras/MAPK 
pathway by growth factor receptors initiates transcription and upregulation of EphA2 at 
the RNA and protein level (77). Utilization of two MEK inhibitors, U0126 and PD98059, 
resulted in a decrease in EphA2 protein levels in a variety of breast cancer cell lines, 
further confirming that this receptor tyrosine kinase is downstream of the MAPK 
pathway (77).  
 An important result of this study was the observation that expression of EphA2 
receptor and ephrinA1 ligand is mutually exclusive in breast cancer cell lines (77). 
EphA2 is overexpressed in the aggressive, mesenchymal-like lines whereas ephrinA1 is 
expressed in the less aggressive, more epithelial-like lines (77). One explanation for the 
lack of EphA2 in ephrinA1 expressing cells is that ligand activation of EphA2 causes 
receptor internalization and subsequent degradation (77).  
 Interestingly, just as the MAPK pathway stimulates EphA2 expression, it is 
simultaneously inhibiting ephrinA1 expression, offering an explanation as to why EphA2 
overexpressing cells lack ephrinA1 (77). Though these cells are not expressing ligand, 
EphA2 can be activated by ligand presented on ligand expressing cells, leading to 
receptor down regulation (77) (Figure 4).  
One exception to this relationship is the MDA-MB-231 breast cancer cell line that 
has an activating mutation in K-Ras and a B-Raf mutation (77-79). These mutations make 
MDA-MB-231 unresponsive to the effects of ligand activation and subsequent MAPK 
pathway inhibition (77). 
 
E-Cadherin 
 Since EphA2 and ephrinA1 are both bound to the plasma membrane and require 
cell-cell contact to interact, it was postulated that E-cadherin, a molecule important in 
mediating adhesion between epithelial cells, might have a role in regulating EphA2 
receptor ligand-dependent activation (59, 80).  
 A comparison of EphA2 cellular localization in nontransformed mammary 
epithelial cells and metastatic cells revealed markedly different distributions of the 
receptor (59). In nonneoplastic cells, EphA2 was localized to those areas where cells 
were coming into close contact (59). However, EphA2 in metastatic cells was localized to 
the membrane ruffles of migratory cells or it displayed a dispersed pattern without 
localization to any specific area (59). Subsequent studies revealed that not only do EphA2 
and E-cadherin colocalize to the points of cell-cell contact, but disruption of E-cadherin 
adhesions resulted in a decrease in the amount of phosphorylated EphA2 and the receptor  
  
 
Figure 4 
Ras Regulation of EphA2 and EphrinA1 Expression 
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then became diffusely distributed, as seen in transformed cells (59). Furthermore, EphA2 
overexpression in metastatic cells respond to induced expression of E-cadherin by 
becoming phosphorylated and localizing to cell-cell adhesion locations (59). 
 Overall, E-cadherin is thought to influence ligand-dependent activation of EphA2 
by stabilizing epithelial cell-cell interactions (59). This stabilization permits binding 
between EphA2 and ephrinA1 and functions to maintain normal levels of the receptor in 
epithelial tissues (59). It’s important to note that a high cell density is not sufficient to 
cause EphA2 phosphorylation and subsequent receptor downregulation, rather, E-
cadherin is the necessary component that creates the strong adhesions between cells and 
allows for ligand-receptor interaction (59). 
 
P53 
 p53 is mutated in a large majority of all cancers (81). Considering that p53 
normally functions to control cell cycle arrest and cell death, it’s not surprising that 
deviation from this regulatory ability would cause havoc on normal cell proliferation and 
could ultimately lead or contribute to cancer development (81, 82).  
 EphA2 contains a binding site for wild type p53 in its promoter indicating that 
p53 is a regulator of EphA2 expression at the transcript and protein levels (83). In 
response to DNA damage, EphA2 tyrosine phosphorylation and upregulation results from 
p53 activation, leading to EphA2-mediated inhibition of cell growth and promotion of 
apoptosis (83). It is possible that p53 activating mutations could function to increase 
protein levels of EphA2, contributing to the overexpression of the receptor in aggressive 
breast cancers (56, 83). 
Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP) 
It is curious that despite the overexpression of EphA2 in some of the most 
aggressive breast cancers, there is limited receptor tyrosine phosphorylation (53, 56, 59). 
Investigation into the mechanism behind the lack of receptor phosphorylation in 
transformed cells has led to the identification of one particular phosphatase, Low 
Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP) (84).  
 Disruption of ligand binding by treating cells with the chemical agent ethylene 
glycol tetraacetic acid (EGTA) or by dominant-negative inhibitors resulted in suppressed 
phosphotyrosine content (59, 84). Furthermore, addition of phosphatase inhibitors after 
treatment of non-neoplastic cells with EGTA hindered the reduction in phosphorylated 
EphA2 (84). Subsequent treatment of breast cancer cells with phosphatase inhibitors 
alone resulted in an increase in the EphA2 phosphotyrosine content (84).  
 These studies led to the identification of LMW-PTP, the phosphatase that 
regulates EphA2 tyrosine phosphorylation. LMW-PTP is highly overexpressed in a 
variety of malignant cell lines, with breast cancer lines being no exception (84). It 
functions to dephosphorylate EphA2, thereby stabilizing the protein at the cell surface 
(84). The oncogenic activity of LMW-PTP depends on this stabilization of non-
phosphorylated EphA2 (84).   
 
 
 
 
 
  
 
Figure 5 
Summary of EphA2 Regulation 
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Metastasis 
 The sequential steps that must be carried out by primary tumor cells in order for 
them to successfully disengage from the initial tumor site and develop disease at distant 
locations are both numerous and complex (85). “Metastasis” is the name given to 
describe this process of disease dissemination to secondary, or more, locations from the 
primary tumor (85). Metastasis involves transformation of cells at the primary site, 
neovascularization, intravasation of transformed cells into circulation, adherence to 
vessels in the secondary location, extravasation of the transformed cells into the 
surrounding organ, response to stimulatory environmental factors, and finally, growth 
within the secondary site (85-87). All of these steps must be completed for metastatic 
success (88). Interestingly, studies have shown that entrance into the circulation by cells 
from mammary adenocarcinomas was relatively common, but less that 0.01% of 
circulating cells survive to develop tumors at metastatic sites (89, 90). This opens debate 
about the existence of a select population of cells from the primary tumor that are 
predisposed to successfully metastasize (89, 91). However, despite the seemingly 
inefficient nature of the metastatic process, metastasis remains the primary contributor to 
high cancer patient mortality rates, including those with breast cancer (85, 92, 93). 
 
 
 
 
EphA2 Involvement in Breast Cancer 
 The RTK EphA2 is a molecule of interest in the study of many cancers, but has 
not been fully investigated in the breast cancer setting. Despite this, there is sufficient 
evidence to support that such a study would be worthwhile and beneficial.  
First, EphA2 has been shown to be overexpressed in both breast cancer cells in 
vitro and in clinical specimens (53). More significant is that this aberrant overexpression 
of EphA2 is seen only in the triple-negative, basal breast cancer subtype, which are 
aggressive and highly metastatic (7, 26, 33). Furthermore, EphA2 overexpression is 
sufficient to cause transformation of non-transformed mammary epithelial cells (53). The 
significance of these findings is that EphA2 is not simply acting as a marker of tumor 
progression, rather, it is a direct player in malignant transformation (56).  
Second, there is a deficit in the amount of available therapies for patients with 
triple-negative breast cancer (33). Since EphA2 has been shown to have a dominant role 
in the progressed state of this disease, investigation into the extent of its participation in 
metastasis is certainly an area of interest (33, 53). Furthermore, EphA2 expression in the 
developed mammary gland is significantly downregulated in comparison to the extent of 
overexpression it exhibits in breast cancers (53, 54). Therefore, it seems likely that 
therapy designed to target EphA2 would cause minimal harmful effects to the 
surrounding, normal mammary tissue.  
Finally, EphA2 is regulated by molecules already associated with advanced stage 
cancers. Examples of such molecules include E-cadherin and ER (59, 75). Loss of cell-
cell contact due to the disruption of E-cadherin mediated adhesions has been implicated 
as a mechanism that facilitates the migration and invasion of tumor cells (59). In addition, 
hormone receptor status is one of the most important features of a patient’s breast cancer 
because of the prognostic ability (75). Upregulation of EphA2 is associated with a 
deregulation in both ER expression and E-cadherin expression yet, the extent of tumor 
dependence on EphA2 overexpression in metastatic breast cancers hasn’t been 
completely elucidated. Exploring the effects of reducing EphA2 in an attempt to 
investigate the biology associated with this receptor’s involvement in the metastatic 
process would contribute to the greater understanding of the progressive mechanics of 
breast cancer.  
 
Specific Aims of the Project 
 The first specific aim of this project was to stably reduce EphA2 receptor levels in 
breast cancer cell lines. The purpose of this aim was to provide proof of the principle that 
when EphA2 expression is low in breast cancer cells, they exhibit a decrease in 
metastatic potential in vitro and negatively affect tumor growth and development of 
metastases in vivo. 
 The second specific aim of this project was to transiently reduce EphA2 levels in 
breast cancer cells using siRNA. The purpose of this aim was to demonstrate that EphA2 
can be reduced in breast cancer cells and in established mammary fat pad tumors and this 
reduction has a negative affect on properties of metastasis in vitro and tumor growth in 
vivo.  
 
 
 
 
  
 
Table 2 
Summary of Notable Characteristics of the Primary Cell Lines Used in 
this Thesis Research 
  
 
 
Cell Line Characteristics 
MDA-MB-231 
- KRAS Mutation 
- BRAF Mutation 
- ER Negative 
- Vimentin Positive 
- EphA2 Expression 
BT549 
- ER Negative 
- Vimentin Positive 
- EphA2 Expression 
HCC 1954 
- HER2/Neu Overexpression 
- ER Negative 
- PR Negative 
- EphA2 Expression 
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Materials & Methods 
 
Cell Lines 
MDA-MB-231 cells were obtained from Dr. Relda Cailleau’s laboratory at the M.D. 
Anderson Cancer Center. These cells were originally isolated from the pleural effusions 
of a breast cancer patient of Caucasian descent. A variant of the original cell line was 
established from metastatic lesions in a nude mouse that had been injected with MDA-
MB-231. These variant cells were then transduced with a lentivirus vector expressing 
luciferase (Lentigen, Baltimore MD). BT549 and HCC1954 were received from the 
American Type Culture Collection. HCC1954 cells were originally isolated from an East 
Indian, female patient with TNM stage IIA ductal carcinoma. BT549 cells were originally 
isolated from a Caucasian, female patient with ductal carcinoma. See Table 2.  
 
Cell Culture Conditions 
MDA-MB-231 Luc cells were maintained in monolayer culture at a temperature of 37°C 
and 5% carbon dioxide (CO2). Minimum essential medium (MEM) supplemented with 
5% fetal bovine serum (FBS), 1% 100mM sodium pyruvate (GIBCO), 1% non-essential 
amino acids (GIBCO), the antibiotics penicillin and streptomycin (GIBCO), L-glutamine, 
and vitamins was used to culture these cells. BT549 cells were maintained in monolayer 
culture at a temperature of 37°C and 5% CO2. Dulbeccos’s modified eagle medium 
(DMEM) supplemented with Ham’s F-12 nutrient mixture, 10% FBS, L-glutamine, and 
penicillin/streptomycin was used to culture these cells. HCC1954 cells were maintained 
in monolayer culture at a temperature of 37°C and 5% CO2. DMEM-High Glucose 
(DMEM-HG) supplemented with 10% FBS, L-glutamine, and penicillin/streptomycin 
was used to culture these cells.  
 
Preparation of Whole Cell Lysates 
Cells were plated in a 6 well plate to achieve a next-day confluency of 70-80%. After 
aspirating the media, cells were washed once with PBS and this was then aspirated as 
well. 10 µl of 10 mg/ml stock PMSF in isopropanol and 10 µl of 100 mM stock sodium 
orthovanadate (Na3VO4) in addition to a Mini, EDTA-free protease inhibitor cocktail 
tablet (Roche Diagnostics) were freshly added to 1 ml of RIPA buffer (50 mM Tris, 150 
mM sodium chloride, 0.1% SDS, 0.5% Sodium Deoxycholate, Triton X 100) and then 
100 µl this mixture was added to each well. The 6 well plate was put on ice so that each 
well could be scraped with a scraper (Corning Incorporated, Costar® 3010), where the 
well contents were then transferred into an appropriately labeled microcentrifuge tube. 
The collected protein lysates were allowed to incubate on ice for 30 minutes to 1 hour. 
After incubating for the specified time, the microcentrifuge tubes containing the protein 
lysates were transferred to a centrifuge where they were spun for 20 minutes at 10,000 
rpm at a temperature of 4°C. The supernatant was collected and transferred to a separate, 
sterile microcentrifuge tube where the protein concentration was then determined using a 
Biorad Protein Assay kit and its protocol in addition to the use of a DU®-65 
Spectrophotometer.   
 
 
 
Immunoblot Analysis 
20 µg of protein collected from the whole cell lysates was combined with Laemmli 
Buffer (Sigma) and boiled for 5 minutes. Protein samples were then separated by sodium 
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) set at 100 volts. After 
separation, protein was transferred to a nitrocellulose membrane (Biorad) also set at 100 
volts. Membranes were blocked using 5% milk in TBST. The following describes the 
primary antibodies used to probe the nitrocellulose membrane and the specific conditions 
required for each: Anti-Eck/EphA2 (Millipore, Cat#05-480) diluted 1:1000 in 5%FBS-
TBST, anti-EGFR (Upstate, Cat#06-847) diluted 1:2000 in TBST only, anti-actin (Sigma, 
Cat#A2066) diluted 1:5000 in 1%FBS-TBST. The following describes the secondary 
antibodies used: Anti-rabbit IgG (Cat#NA934V) and anti-mouse IgG (Cat#NA931V) 
secondary antibodies (Amersham Life Science ECL Western Blitting Analysis System). 
GE Healthcare ECL Western Blotting Detection Reagents (Cat#RPN2106) were used for 
detection.  
 
Isolation of RNA and Quantitative Real Time Polymerase Chain Reaction 
Cells were plated in a 6 well plate and grown to 70-80% confluency. RNA was isolated 
using the Array Grade Total RNA Isolation Kit (SA Biosciences, Cat#GA-013) according 
to its protocol. Isolated RNA was then treated with TURBO DNA-free reagents (Ambion, 
Cat#AM1907) and made into cDNA by the process of reverse transcription using the 
High Capacity DNA Archive reagents (Applied Biosystems). Each test well on the PCR 
plate had a total reaction volume of 25 µl which was a mixture of 1.25 µl of 20X Gene 
Expression Assay Mix (Applied Biosystems), 12.5 µl of 2X TaqMan Universal PCR 
Master Mix (Applied Biosystems), and 11.25 µl of 200 ng cDNA that was diluted in 
RNase-free water. Duplicates of each sample were tested with 18S in each sample tested 
as the intrinsic positive control. After plate preparation, the 7500 Real-Time PCR System 
(Applied Biosystems) was used to carry out the reaction and data was converted into 
cycle threshold (∆CT) measurements. qRT-PCR was performed for EphA2 and EGFR in 
this way.  
 
siRNA Transfection 
Cells were grown in a 6 well plate to 70-80% confluency. The next day, transfection 
mixtures were prepared. Control cells were treated with 400 µl of serum-free medium 
only. Control cells for the transfection reagent were treated with 400 µl of serum-free 
medium with 12 µl of HiPerFect Transfection Reagent (Qiagen, Cat#301705). Cells 
treated with the non-targeting siRNA were treated with 400 µl of serum-free medium, 12 
µl of HiPerFect Transfection Reagent, and 1.5 µl of the negative control siRNA (Ambion, 
Cat#AM4613). Cells treated with EphA2-targeting siRNA #1 were treated with 400 µl of 
serum-free medium, 12 µl of HiPerFect Transfection Reagent, and 1.5 µl of the EphA2-
targeting siRNA ID: 146479 (Ambion, Cat#AM16708A). Cells treated with EphA2-
targeting siRNA #2 were treated with 400 µl of serum-free medium, 12 µl of HiPerFect 
Transfection Reagent, and 1.5 µl of the EphA2-targeting siRNA ID: 242385 (Ambion, 
Cat#AM16708). After preparation of transfection mixtures, culture medium was 
aspirated, mixtures were added to the appropriate wells, and cells were incubated for 5-6 
hours. After incubation, 1.9 ml of the appropriate serum-containing medium was added to 
each well and cells were incubated for 72 hrs at which point they would be used for 
various assays.  
 
Migration Assay 
Approximately 1x105 cells were plated into the upper, non-coated chamber of one of 24 
well inserts with an 8 micron pore size (BD Biosciences, Cat#354578). Cells were plated 
in serum-free medium in the upper chamber and were placed in the lower chamber which 
contained either serum-free medium + 0.1%BSA or serum-free medium containing 
0.1%BSA and EGF (Invitrogen, Cat#13247-05) as a chemoattractant. Migration plates 
were placed in the incubator and cells were allowed to incubate for 6 hours. Cells that did 
not migrate were wiped away with a cotton swab. Cells that had migrated to the lower 
surface of the membrane were fixed and stained with the Fisher HealthCare PROTOCOL 
Hema 3 Manual Staining System (Fisher Scientific Company L.L.C.). Membranes were 
allowed to dry before being cut away from the chamber and placed on microscope slides 
(Fisher Scientific, Cat#15-188-51) with PerMount (Fisher Scientific) and covered with a 
cover slide (Corning 24x40mm, Cat#2935-244). Migrated cells were then counted.  
 
ELISA for VEGF 
2.5x105 cells were plated in a 6-well plate. The next day, the medium was aspirated and 
1ml of medium was added back in overnight and supernatant was collected the next day. 
VEGF capture antibody (R&D Systems, Cat#AF-293-NA) was added to a 96 well E1A 
plate (Costar 9018) the day before ELISA was performed. Wells were then washed with 
wash buffer (PBS+0.05%Tween 20) and blocking solution was added (PBS with 1% 
BSA, 5% sucrose, 0.05% sodium azide) for 1 hour. Wells were washed with wash buffer. 
VEGF standards (R&D Systems, Cat#293-VE) and sample supernatants were added to 
appropriate wells for 2 hours. Wells were washed with wash buffer. VEGF detection 
antibody (R&D Systems, Cat#BAF293) was added to the wells for 2 hours. Wells were 
washed with wash buffer. Streptavidin HRP (R&D Systems, Cat#DY998) was added to 
wells for 20 min. Wells were washed with wash buffer. Substrate solution [1:1 mixture of 
color reagent A (H2O2) and color reagent B (tetramethylbenzidine), R&D Systems, 
Cat#DY999] was added to wells for 25 min. Stop solution (1M H2SO4) was added to the 
wells. Plate was read within 30 min. using the DU®-65 Spectrophotometer and VEGF 
concentrations were calculated based on standard curve values.   
 
Co-Immunoprecipitation Assay 
5x106 cells were plated in a 10 cm dish with 10 ml medium. When cells were 80% 
confluent, they were serum starved overnight and stimulated with 50ng/ml EGF for 15 
minutes the next day. The medium was aspirated, cells were washed once with cold PBS, 
and 1ml of cold PBS was added to the dish to collect the cells. Cells were centrifuged at 
4°C at 3000rpm for 5-10 minutes. The supernatant was dumped and cell pellets were 
lysed with 500 ml TNE buffer with inhibitors. Cell and buffer mixture was allowed to 
rotate for 1 hr at 4°C and then spun down at 12,000 rpm for 15 minutes at 4°C. The 
supernatant was transferred into a clean tube and the protein concentration was measures. 
Samples consisting of 20 µg of protein were prepared and set aside to be used for whole 
protein lysates control. 100 µg protein was taken from each protein sample and mixed 
with TNE buffer to take the total volume up to 1 ml. 5 µg of anti Eck/EphA2 antibody 
(Millipore, Cat#05-480) was added to each sample and allowed to rotate at 4°C 
overnight. The next day, 25 µl of beads was taken per sample and washed with 1 ml TNE 
buffer three times. After washing, TNE buffer was added to the bead volume in a 1:1 
ratio. 25 µl of the bead/TNE buffer mixture was added to each 100 µg protein sample and 
was allowed to rotate for 1-2 hrs at 4°C. Samples were spun down and beads were 
washed with 1 ml TNE buffer three times. 2x Laemmli buffer was added in a 1:1 ratio to 
the protein samples and also to the aliquots of 20 µg whole protein samples. All samples 
were boiled for 5 minutes. Proteins were then subjected to SDS-PAGE and western blot 
analysis to look at EGFR protein expression.  
 
Lentiviral Delivery of shRNA for Stable Silencing of EphA2 
Knockdown cell lines were made by using the Invitrogen website BLOCK-iT RNAi 
Designer to find shRNA sequences that had been ranked to indicate knockdown 
probability. Three highly rated EphA2 target shRNA sequences were selected: LV3: 
GGCTGAGCGTATCTTCATTGA; LV4: GCGTCATCTCCAAATACAAGC; LV5: 
GGTGATGAAAGCCATCAATGA. Sequence information was provided to the Viral 
Core Laboratory of the Department of Cancer Biology to prepare lentivirus with shRNA 
to EphA2. Sense and antisense EphA2-targeting oligonucleotides and a non-targeting 
control shRNA oligonucleotide (TTCTCCGAACGTGTCACGT) were created to have a 
hairpin structure and sticky ends. The EphA2 targeting and non-targeting shRNA 
oligonucleotides were then cloned into the pLVTHM expression vector (Addegene, 
Cat#12247). EphA2 shRNA knockdown lentivirus and non-targeting shRNA lentivirus 
were generated by transfecting the packaging plasmid (2nd generation including PAX2 
and MD2G; Addgene, Cat#12259 and 12260) with the EphA2 expression plasmid into 
293T cells. MDA-MB-231 Luc and BT559 cells were plated and grown to 70% 
confluency. Control cells were treated with 250 µl of non-targeting control virus, 750 µl 
of regular medium, and 3µg/ml of polybrene. Test cells were treated with 500 µl of either 
LV3, LV4, or LV5 in addition to 500 µl of regular medium and 3 µg/ml of polybrene. 
Cells were incubated with the virus mixtures for 24 hours, after which the mixtures were 
aspirated and fresh medium was added. Cells were incubated and allowed time to grow. 
Cells were sorted at the M.D. Anderson Cell Sorting Facility based on expression of 
GFP.   
 
Agarose Colony Formation Assay 
Standard 2x MEM was prepared from 10x MEM liquid. 20 ml of the 10xMEM, 75 ml of 
double distilled H2O, 2.9 ml of sodium bicarbonate (7.5% solution), and 2.1ml of pen-
strep solution were mixed together. After mixing, the solution was filtered for 
sterilization and stored. To begin the assay, 1% and 0.6% agarose solution needed to be 
made from standard 2% agarose. The 2% agarose solution was warmed in the microwave 
and then mixed 1:1 with 2x MEM to make 1% agarose solution. In order to make 0.6% 
agarose solution, the 1% agarose solution was further diluted using serum-free MEM. 
1ml of 0.6% agarose solution was added to each well of a 6 well plate, or according to 
how many samples there were including a duplicate. The 0.6% agarose solution was 
spread quickly and left in the hood to solidify. Cells were harvested and counted. The cell 
layer was mixed in proportions of 1% agarose, serum-free MEM, FBS (either to make 
10% or 1% FBS), and cell suspensions in order to achieve a concentration of 0.3% 
agarose, 10% or 1% FBS, and 1x103 cells in a final volume of 1.5 ml. 1.5 ml of each cell 
solution is now added to the appropriate well on top of the 0.6% base agarose layer. The 
plates were allowed to sit at room temperature for 30 min-1 hr before being put in the 
incubator for approximately 14-21 days. Every couple of days, a small amount of 
medium (0.5 ml) was added to the agarose cultures to prevent the gel from drying.  
 
Immunocytochemistry for Fluorescent and Confocal Imaging 
Cells were plated on chamber slides at 7x104 cells per chamber and incubated overnight. 
The next day cells were fixed with acetone, washed with PBS, and blocked with protein 
block (4% Fish gelatin in PBS, supplied by the Core Facility). EphA2 antibody 
(Millipore, Cat#05-480) was applied to cells and incubated in the cold room overnight. 
Cells were washed, protein blocked, and secondary antibody was applied for 1 hour. 
Alexa 488 goat-anti-mouse (MolPrb, Cat#A11029) secondary antibody was used to stain 
cells for fluorescent imaging and cy3 goat-anti-mouse secondary antibody was used to 
stain cells for confocal imaging (Jackson ImmunoResearch, Cat#111-166-047). Cells 
were washed, protein blocked, and the EGFR primary antibody (Santa Cruz, Cat#sc-03) 
was applied overnight in the cold room. Cells were washed, protein blocked, and EGFR 
secondary antibody was added for 1 hour at room temperature. Alexa 594 anti-rabbit 
secondary (Invitrogen, Cat#A11037) was used to stain cells for fluorescent imaging and 
cy5 donkey-anti-rabbit secondary (Jackson ImmunoResearch, Cat#711-176-152) was 
used to stain cells for confocal imaging. Cells were washed and counterstained with 
Hoescht (for fluorescent imaging of nuclei; Invitrogen, Cat#H3570) or cytox green (for 
confocal imaging of nuclei). Cells were washed, slides were mounted with propylgallate, 
covered, and stored in the cold room protected from light.    
 
Animals 
Female athymic nude (NCr-nu/nu) mice were purchased from the Charles River 
Laboratory (Wilmington, MA) when they were four to five weeks old. The animals were 
housed in a facility that is approved by the American Association for Accreditation of 
Laboratory Animal Care.  
 
Mammary Fat Pad Tumor Growth 
Each experimental group consisted of 5-10 mice. Mice were anesthetized using Metofane 
(Pitman Moore, Inc.; Washington, NJ). Once anesthetized, an incision approximately 5 
mm in length was made in the skin covering the lateral thorax to expose the mammary fat 
pad. A 27 gauge needle was used to inject 5x106 cells in 0.1 ml PBS into the mammary 
fat pad of each animal.  
 
Experimental Metastasis 
1x106 breast cancer cells suspended in a volume of 0.2 ml PBS were injected 
intravenously (i.v.) in the lateral tail vein of each mouse. A total of 5-10 mice were used 
per experimental group. Animals were watched closely until they were approaching death 
or until 10 weeks post injection. At either of these time points, the animals were 
sacrificed and the lungs were collected to be examined for metastases. Additionally, since 
the MDA-MB-231 Luc cells contain a luciferase gene, animals were monitored for lung 
metastases approximately three weeks post-i.v. injection of the cells. Mice were injected 
i.p. with 0.2 ml of 15 mg/ml luciferin and imaged for bioluminescence using a Xenogen 
IVIS Imaging System. The extent of bioluminescence could be measured using the ROI 
(Region of Interest) tool provided in the imaging software. 
 
Liposomal and Chitosan Nanoparticle Treatment 
Cells that had been injected into the mammary fat pad were allowed to grow until tumors 
were established and had reached an approximate volume of 75 mm3. Concurrently, the 
DOPC liposomes and nanoparticles containing control or EphA2-targeting sequences 
were prepared and provided by the laboratories of Dr. Anil Sood and Dr. Gabriel Lopez-
Berestein using siRNA sequences purchased from Sigma Genosys. siRNA known and 
shown to target EphA2 mRNA (5’-UGACAUGCCGAUCUACAUG-3’) and siRNA 
known and shown to have no human mRNA target (5’-UUCUCCGAACGUGUCACGU-
3’) were used for liposomal and nanoparticle incorporation. Briefly, incorporation of 
DOPC and siRNA involved mixing the two in the presence of tertiary butanol, then 
Tween 20 was added, and finally an acetone/dry ice bath was used to freeze the mixture 
before being lyophilized (95). Preparation of the siRNA and nanoparticles involved the 
addition of TPP (thiamine pyrophosphate) and siRNA to a chitosan nanoparticle solution 
where the siRNA chitosan nanoparticles spontaneously formed (96). PBS, DOPC 
liposomes, or chitosan nanoparticles were injected i.v. twice weekly (150 µg/kg) for four 
weeks. Those groups that also received chemotherapy were injected i.p. with paclitaxel 
(24 mg/kg) once weekly in a PBS-glucose solution for four weeks. At the end of the 
study, tumors were weighed and tumor tissue was collected for frozen sections, paraffin 
sections, and it was snap frozen for protein isolation.  
 
Homogenization of Tumor Tissue for Protein Analysis 
During mammary fat pad tumor collection, some tissue was snap frozen in liquid nitrogen 
for later protein analysis. Samples were homogenized while still frozen in TNE lysis 
buffer that consists of 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 2 mM EDTA, 1 mM 
Na3VO4, 1 mM PMSF, and an inhibitor cocktail tablet. After homogenization, NP-40 
(Sigma, Cat#N-6507) was added to each sample (1%v/v) and mixed well. Samples were 
incubated on ice for 30 min-1 hr. Homogenized tissues were then centrifuged at 10,000xg 
for 10 minutes at 4°C. The supernatant was removed and transferred to a clean 
microcentrifuge tube where it was centrifuged again. This process continued until a clear 
lysate was obtained. Protein concentrations could then be measured and were subjected to 
western blot analysis.  
 
Immunohistochemistry for CD31 on Frozen Sections 
Slides were fixed in acetone, washed, and incubated in 3% H2O2 in methanol. Sections 
were then protein blocked and the primary antibody (BD Pharmingen, Cat#553370) was 
added 1:1000 in protein block overnight at 4°C. The next day, slides were washed and the 
HRP secondary antibody (Jackson ImmunoResearch, Cat#112-035-167) was added 1:200 
in blocking solution for 1hr at room temperature. Slides were washed, diaminobenzidine 
(DAB; Research Genetics, Cat# ) was added, and then rinsed. Sections were 
counterstained with Gill’s Hematoxylin and rinsed. Finally, sections were allowed to dry 
and were mounted with Universal Mount.                   
 
Immunohistochemistry on Paraffin Embedded Tissue 
For Ki-67 staining, slides were dewaxed. Antigen retrieval in citrate buffer (0.1M) was 
carried out. Slides were washed, incubated in endogenous peroxide blocking solution 
(3% hydroxyperoxide), and washed again. Protein blocking solution (TBST + 5%NGS) 
was applied to the slides for 1hr at room temperature. Primary antibody (Epitomics, 
Cat#4203-1) was added 1:200 in blocking solution and incubated at 4°C overnight. Slides 
were washed and secondary antibody (Jackson ImmunoResearch, Cat#111-036-047) was 
applied to sections 1:250 in blocking buffer and incubated for 1hr at room temperature. 
Slides were washed and incubated in DAB. Slides were washed, stained with 
hematoxylin, washed again, and then left to air dry before being mounted in Permount. 
For cleaved caspase 3 staining, slides were processed (de-waxed, antigen retrieval, and 
blocked for endogenous peroxidase) as described above. Antibody to cleaved caspase 3 
(Cell Signaling, Cat#9661) was diluted 1:200 in protein blocking solution and incubated 
overnight at 4°C. The secondary antibody, DAB, and hemotoxylin counterstain was as 
described above.  
 
Densitometry 
The Image J program was downloaded and used to quantify protein levels revealed by 
western blot analysis. Each protein band was compared to its corresponding actin band by 
calculating the ratio. This ratio could then be compared with the other sample ratios.  
Statistical Analysis 
The results of the in vitro and in vivo studies were analyzed for their significance using 
the Student’s T-test. A p-value of less than or equal to 0.05 was considered statistically 
significant. Calculations were carried out using Microsoft Office’s Excel application.  
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Introduction 
 Stably reducing the levels of EphA2 in breast cancer cells was necessary in order 
to demonstrate that cells with low EphA2 expression would have decreased metastatic 
potential. Introducing synthetic siRNA into cells and allowing the natural cellular RNA 
interference process to use these siRNAs to silence protein expression is a powerful way 
to study the effects of EphA2 knockdown in metastatic breast cancer cell lines and in 
mouse xenograft models (97). However, a drawback of this method of RNAi pathway 
activation is that the effect of receptor expression silencing is transient, lasting only a few 
days (97). An alternative method of RNAi pathway activation can be mediated through 
the use of shRNAs (97). Plasmid vectors containing shRNA for the gene of interest can 
be inserted into a packaging cell lines which also contains plasmids encoding lentiviral 
proteins (97, 98). The gene of interest is then packaged into the virus which can be used 
to transduce a particular cell line where it will be randomly inserted into the host cell 
genome and will ultimately be incorporated into the RNAi pathway (97, 98).   
 Direct cellular delivery of siRNA, subsequent processing by the enzyme Dicer, 
and incorporation into RISC occurs in the cytoplasm of the cell (97, 98). While shRNA 
processing also occurs in the cytoplasm by Dicer, it is first processed in the nucleus by an 
enzyme called Drosha before cytosolic exportation (97, 98). This second method of 
RNAi pathway activation offers the advantage of longer-term silencing (98). The 
significance of this long-term silencing is that it allows investigation into the effects of 
EphA2 receptor depletion over a period of time when the cellular mechanics are stably 
altered (98). The mechanism of using lentiviruses containing EphA2 targeting sequences 
for stable receptor depletion was adopted in order to conduct in vitro and in vivo studies.  
 Three EphA2-targeting sequences were separately inserted into lentivirus vectors 
in an attempt to achieve a stable knockdown of EphA2 receptor levels. These three 
viruses are termed LV3, LV4, and LV5. Additionally, there is control lentivirus that 
contains a scrambled, non-targeting sequence and it is termed LVNC. These virus names 
were used throughout the experiments to designate the cells that were transduced with a 
specific lentivirus. For example, MDA-MB-231 Luc cells transduced with LV3 were then 
termed MDA-MB-231 Luc LV3.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results: In vitro Studies 
 
Demonstration of Stable EphA2 Knockdown in MDA-MB-231 Luc, HCC1954, and 
BT549 Breast Cancer Cell Lines after Transduction with Lentivirus Containing 
EphA2-Targeting Constructs  
Lentiviruses were designed that contained EphA2-targeting constructs for the purpose of 
stable protein knockdown. One (LV3) of the three (LV3, LV4, LV5) viruses created, 
each containing a unique targeting sequence, turned out to effectively reduce EphA2 
receptor levels stably compared to the control (LVNC) that contains a non-targeting 
sequence. After transduction, cells were sorted based on GFP expression which indicates 
successful uptake and integration of viral information into the target cells. BT549 and 
MDA-MB-231 Luc cells transduced with LV3 showed the most significant protein 
reduction as revealed by western blot analysis and subsequent densitometry analysis. 
Further qPCR analysis confirmed the knockdown of EphA2 in the LV3 cell lines (data 
not shown) (Figure 6).  
 
 
 
 
 
 
  
Figure 6. Demonstration of EphA2 Knockdown in MDA-MB-231 Luc, HCC1954, 
and BT549 Cell Lines after Transduction with Lentivirus 
(A) Western blot analysis of protein lysates collected from HCC1954 cells that had been 
left untreated, treated with lentivirus containing a non-targeting construct, or treated with 
one of two lentiviruses containing EphA2-targeting constructs revealed that LV3 was 
most successful at reducing EphA2 protein levels (left). Actin was used as a control to 
ensure equal protein loading. Densitometry analysis confirmed the results of the western 
blot (right). LV3 was not as successful at stably reducing EphA2 protein levels in this cell 
line in comparison to the other two cell lines. (B) Western blot analysis of protein lysates 
collected from MDA-MB-231 Luc cells that had been left untreated, treated with 
lentivirus containing a non-targeting construct, or treated with one of three lentiviruses 
containing EphA2-targeting constructs revealed that LV3 was most successful at 
reducing EphA2 protein levels (left). Actin was used as a control to ensure equal protein 
loading. Densitometry analysis confirmed the results of the western blot (right). (C) 
Western blot analysis of protein lysates collected from BT549 cells that had been left 
untreated, treated with lentivirus containing a non-targeting construct, or  treated with one 
of three lentiviruses containing EphA2-targeting constructs revealed that LV3 was most 
successful at reducing EphA2 protein levels (left). Actin was used as a control to ensure 
equal protein loading. Densitometry analysis confirmed the results of the western blot 
(right). 
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MDA-MB-231 Luc and BT549 Cells Transduced with LV3 Show Reduced 
Migration Towards the Chemoattractant EGF Compared to the Control 
MDA-MB-231 Luc cells treated with lentivirus containing either the non-targeting 
control or EphA2-targeting construct were plated in a transwell chamber and stimulated 
by either 0.1%BSA or 50ng/ml EGF. MDA-MB-231 Luc LV3 cell migration was 
attenuated when stimulated by EGF in comparison to the 231 Luc LVNC cells where the 
number of migrated cells towards EGF was greater than towards 0.1%BSA. This result 
was significant when the number of MDA-MB-231 Luc LV3 cells that had migrated 
towards EGF was compared to the MDA-MB-231 Luc LVNC cells that had migrated 
towards EGF (Figure 7a). This migration experiment was repeated in the BT549 cell lines 
that had been transduced either by the EphA2-targeting lentivirus or the non-targeting 
lentivirus. The result was similar to that seen with the MDA-MB-231 Luc cells where the 
BT459 LV3 cells showed attenuated migration when compared to the BT549 LVNC cells 
(Figure 7b).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 7. Cells Transduced with LV3 Showed Attenuated Migration Towards EGF 
(A) MDA-MB-231 Luc LV3 and LVNC cells were plated in the upper chamber of a 
BioCoat transwell and stimulated with either 0.1% BSA or 50µg/ml EGF. The LV3 cells 
which have stably reduced EphA2 receptor levels showed attenuated migration in 
response to EGF when compared to the migration exhibited by the LNVC cells in 
response to EGF. This result is statistically significant when analyzed using the Student’s 
T-test (p-value = 0.001). (B) BT549 LV3 and LVNC cells were plated in the upper 
chamber of a BioCoat transwell and stimulated with either 0.1% BSA or 50µg/ml EGF. 
The LV3 cells which have stably reduced EphA2 receptor levels showed attenuated 
migration in response to EGF when compared to the migration exhibited by the LNVC 
cells in response to EGF, but this finding was not significant (p-value = 0.9).   
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MDA-MB-231 Luc cells with Stably Reduced EphA2 Levels Show No Change in 
Anchorage Independent Growth Capability 
The ability of cells to grow and colonize in soft agar indicates that they are malignant 
(99). Since EphA2 has been found to play a role in other hallmark processes of cancer 
such as migration and angiogenesis, it was thought that maybe it plays a role in 
anchorage independent proliferation and growth as well. 231 Luc, 231 Luc LVNC, and 
231 Luc LV3 cells were suspended in soft agar containing either 1%FBS or 10%FBS. At 
the end of two weeks, the colonies that had formed were counted. There was no 
significant difference between the cell lines, revealing that reducing the receptor levels of 
EphA2 does not affect the anchorage independent growth characteristic of these breast 
cancer tumor cells (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 8. Reduced Levels of EphA2 Do Not Affect Anchorage Independent Growth 
(A) MDA-MB-231 Luc, MDA-MB-231 Luc LVNC, and MDA-MB-231 Luc LV3 cells 
were plated in either 10% FBS or 1% FBS agarose solution and allowed to grow for 14 
days. All cell lines showed a reduced number of cell colonies formed per field when 
plated in 1% FBS agarose solution and showed an increase in the number of cell colonies 
formed per field when plated in the agarose solution containing 10% FBS. The reduction 
in EphA2 receptor levels did not affect the ability of breast cancer cells to colonize 
independent of adherence and in reduced FBS conditions.  
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Results: In vivo Studies 
 
Mammary Fat Pad Tumor Growth was Reduced in Mice Injected with the Stable 
MDA-MB-231 Luc LV3 Cell Line 
Female athymic nude mice were injected in the mammary fat pad with either MDA-MB-
231 Luc LVNC or MDA-MB-231 Luc LV3 cells to observe any differences in the 
tumorigenic ability between the two cell lines. Ten mice were injected with the LVNC 
cell line and ten mice were injected with the LV3 cell line. Tumor measurements were 
recorded and tumor volumes were calculated. Averages of the tumor volumes for each 
time point in each group were compared. Over the course of five and a half weeks, the 
mammary fat pad tumors of mice injected with MDA-MB-231 Luc LV3 cells showed a 
decrease in growth compared to the control group (Figure 9a). This indicates that EphA2 
plays a role in tumorigenicity in vivo. Furthermore, analysis of the tumor weights of the 
LVNC and LV3 MFP tumors revealed a decrease in the average weight of the LV3 MFP 
tumors when compared with the LVNC average tumor weight (Figure 9b).  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 9. Mammary Fat Pad Tumors with Stably Reduced EphA2 Showed 
Decreased Tumor Growth 
MDA-MB-231 Luc LVNC and MDA-MB-231 Luc LV3 cells were injected into the 
mammary fat pads of female athymic nude mice. After the tumors were established, the 
tumor dimensions were recorded and volumes were calculated. (A) Over the course of 
5.5 weeks, the mammary fat pad tumors of the mice injected with the LV3 cells showed 
reduced tumor growth compared to the mammary fat pad tumors of those mice injected 
with the LVNC cells. This difference was significant as determined by the Student’s T-
test (p-value = 0.04) and was reproduced after a repeat experiment was conducted. (B) At 
the time of mice sacrifice, the MFP tumors were collected and weighed. Average tumor 
weight of the LVNC group is higher compared to the LV3 group. This data was not 
statistically significant (p-value = 0.347).   
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Tumor Protein Analysis Revealed Decreased EphA2 Protein Levels in the 
Mammary Fat Pad Tumors of Mice Injected with MDA-MB-231 Luc LV3 Cells 
Having seen a reduction in mammary fat pad tumor growth in those mice that were 
injected with the MDA-MB-231 Luc LV3 cell line, the next step was to analyze the 
protein content of the tumor tissue to assess whether the decrease in tumor growth 
correlated with a reduction in tumor EphA2 protein levels. Western blot analysis revealed 
that EphA2 is reduced in the MDA-MB-231 Luc LV3 mammary fat pad tumors 
compared to the MDA-MB-231 Luc LVNC mammary fat pad tumors (Figure 10a). 
Further densitometry analysis confirmed a reduction in EphA2 levels in the MDA-MB-
231 Luc LV3 mammary fat pad tumors relative to the average EphA2 content found in 
the control tumors (Figure 10b). Since a reduction in EphA2 led to a reduction in EGFR 
in the transient knockdown in vitro studies, the stable mammary fat pad tumor tissue 
protein lysates were also analyzed for EGFR protein levels (Figure 10a,c). It appears that 
there is a trend in EphA2 and EGFR protein levels in the stable mammary fat pad tumors 
where a reduction in EGFR correlated with the decrease in EphA2 protein levels. This 
trend was confirmed by densitometry analysis. While these data indicates a correlation in 
EphA2 protein levels and tumor growth, it was not found to be statistically significant.  
 
 
 
 
 
 
 
 
 
  
Figure 10. EphA2 Protein Levels Were Decreased in Mammary Fat Pad Tumors 
with Stably Reduced EphA2 
(A) Protein was isolated from MDA-MB-231 Luc LVNC and MDA-MB-231 Luc LV3 
mammary fat pad tumor tissue and subjected to western blot analysis to reveal EphA2, 
EGFR, and actin protein levels. Actin was blotted for to ensure that equal amounts of 
protein were loaded. 20µg of protein was loaded into each lane. Lanes 1-5 represent five 
distinct MDA-MB-231 Luc LVNC mammary fat pad tumors and lanes 6-10 represent 
five distinct MDA-MB-231 Luc LV3 mammary fat pad tumors. (B) Densitometry 
analysis confirmed the data obtained from the western blot analyses. The individual 
EphA2 protein densities of the MDA-MB-231 Luc LVNC mammary fat pad tumors were 
compared to their respective actin densities (EphA2/actin) and then all of the individual 
LVNC protein densities were averaged and the average was divided by itself to obtain a 
reference point of 1. The individual EphA2 protein densities of the MDA-MB-231 Luc 
LV3 mammary fat pad tumors were compared to their respective actin densities 
(EphA2/actin) and the divided by the average of the LVNC densities to show the amount 
of EphA2 protein reduction in the individual LV3 mammary fat pad tumors relative to the 
negative control mammary fat pad tumors. (C) The same method of densitometry 
analysis described in (B) was applied to the EGFR protein densities to show a correlation 
in EphA2 reduction and EGFR reduction.   
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The MVD in MDA-MB-231 Luc LV3 Mammary Fat Pad Tumors was Reduced 
Compared to the MVD in MDA-MB-231 Luc LVNC Mammary Fat Pad Tumors 
Previous tumor growth and tumor protein analysis indicated that the MDA-MB-231 Luc 
LV3 cells exhibited slower growth and also had reduced amounts of EphA2 protein when 
compared to the control tumors. Since angiogenesis, like proliferation, is a hallmark of 
cancer, it was hypothesized that reduced EphA2 would also affect vessel growth and 
formation in the MDA-MB-231 Luc LV3 tumors. CD31 staining was carried out on 
tissue sections prepared from MDA-MB-231 Luc LVNC and MDA-MB-231 Luc LV3 
mammary fat pad tumors (Figure 11a,b). Tissue sections were observed under 20x 
magnification and vessel density was quantified by counting the number of individual 
vessels inside a 0.25 x 0.25mm grid. Tumor vessel density was modestly, but 
significantly reduced in the MDA-MB-231 Luc LV3 tissue sections when compared to 
the MDA-MB-231 Luc LVNC vessel density (Figure 11c). Staining for Ki-67 and 
cleaved caspase 3 was also done, although, this data was uninformative because it did not 
reveal a difference between the LVNC and LV3 tumor tissue samples (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 11. Reduced MVD in MDA-MB-231 Luc LV3 Mammary Fat Pad Tumors 
Compared to MDA-MB-231 Luc LVNC 
(A) CD31 stained MDA-MB-231 Luc LVNC tumor tissue sections revealed a high 
microvascular density and more vessels with visible lumens. (B) CD31 stained MDA-
MB-231 Luc LVNC tumor tissue sections revealed a lower microvascular density with 
fewer vessels having visible lumens when compared to the LVNC stained tissue sections. 
(C) Vessel density was counted in ten different locations within one tumor section (each 
tumor section being from a different mouse mammary fat pad tumor) and then averaged 
to get a representative number of vessels per field. Quantification of the vessel density 
revealed a statistically significant (p-value = 0.002) reduction in the number of vessels 
per field in the CD31 stained MDA-MB-231 Luc LV3 tumor tissue sections.    
 
 
 
 
 
 
Figure 11 
Reduced MVD in MDA-MB-231 Luc LV3 Mammary Fat Pad Tumors Compared to 
MDA-MB-231 Luc LVNC  
 
(A) MDA-MB-231 Luc LVNC CD31 Tumor Tissue Staining    
   
 
 
 
 
 
 
 
 
 
 
(B) MDA-MB-231 Luc LV3 CD31 Tumor Tissue Staining 
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MDA-MB-231 Luc LV3 Cells Develop Fewer Experimental Lung Metastases in 
Comparison to LVNC Cells After Intravenous Injection into Mice 
Athymic female nude mice were injected i.v. with either MDA-MB-231 Luc LVNC or 
MDA-MB-231 Luc LV3 cells in order to observe the efficiency of the two cell lines in 
developing experimental metastases. Intravenous injections allows for cell circulation and 
ultimate arrest in the capillary beds of various tissues. The development of lung 
metastases was measured using the IVIS (Caliper) after i.p. injection of luciferin. 
Luciferin is oxidized in the presence of luciferase (expressed by the MDA-MB-231 Luc 
cells) and light energy is a by-product. This light energy, or luminescence, can be 
detected and quantified by the IVIS machine. Based on initial readings at 3 and 4 weeks 
after injection, more mice in the LVNC group developed lung metastases compared to the 
LV3 group (Figure 12a). This suggests that breast cancer cells with reduced EphA2 are 
not as efficient at developing lung metastases as the cells that over express EphA2.  
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 12. Breast Cancer Cells with Stably Reduced EphA2 Expression Do Not 
Develop Lung Metastases As Efficiently as Breast Cancer Cells Overexpressing 
EphA2 
MDA-MB-231 Luc LVNC or LV3 cells were injected intravenously into athymic female 
nude mice. 1x106 cells suspended in 0.2ml PBS were injected in each mouse and there 
were 10 mice per cell line. (A) Four weeks post-i.v. injection, the mice were imaged after 
being injected i.p. with 0.2ml of luciferin (15mg/ml). Imaging of the LVNC mice 
revealed lung metastases in 5 of the 9 mice (the two upper images). This number had 
increased from imaging done the week before where only 2 of the 9 mice displayed lung 
metastases. In contrast, imaging of the LV3 mice revealed that only one of the ten mice 
had a lung metastasis and another mouse had a possible bone metastasis (the two upper 
lower images). There was no additional development of lung metastases or other bodily 
metastases in these two mice when compared to imaging done the previous week, and the 
additional mice in the LV3 group had still not developed metastases at all.  
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Breast Cancer Cells with Stably Reduced EphA2 Expression Do Not Develop Lung 
Metastases As Efficiently as Breast Cancer Cells Overexpressing EphA2 
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Discussion: Utilize Targeted shRNA to Study the Effects of Stable 
EphA2 Reduction In vitro and In vivo  
 
 The goal of Specific Aim I was to develop a stable knockdown of EphA2 in 
metastatic breast cancer cell lines to study the effect of receptor depletion over an 
extended period of time. Metastatic breast cancer cell lines with a stable knockdown of 
EphA2 were used to complete in vitro experiments for properties indicating metastatic 
potential that have helped to confirm the findings of the transient siRNA experiments, in 
which EphA2 was only maximally reduced for a few days. Use of these cell lines with 
stably depleted EphA2 expression also assisted in determining how EphA2 influences 
tumorigenicity in vivo, a process that cannot be successfully studied using transient 
siRNA-mediated knockdown. These in vitro and in vivo experiments have helped to 
reinforce the hypothesis that EphA2 contributes to the ability of breast cancer cells to 
metastasize.  
 First and foremost, it was imperative to find a way to stably reduce EphA2 
receptor expression in metastatic breast cancer cell lines. The first attempt involved the 
transformation of competent bacterial cells by introducing EphA2 shRNA construct-
containing plasmids to the cells and subsequently amplifying the cultures. In addition to 
containing an EphA2 shRNA construct, the plasmids also carried a puromycin resistance 
gene so that transfected cells could be selected for based on their resistance. Despite 
successful transfection of the cells with the EphA2 shRNA-containing plasmids 
(assuming puromycin resistance is indicative of successful cellular uptake of the 
plasmid), there was no reduction in EphA2 receptor levels, or if there was, it was too 
minimal to expect significant results if used for in vitro and in vivo experiments. After 
several unsuccessful attempts to stably reduce EphA2 after plasmid transfection, a 
mixture of 3-5 lentiviral vector plasmids with shRNA sequences targeting EphA2 were 
purchased from Santa Cruz in hopes that this alternative method would proved the 
desired stable knockdown. However, these lentiviral particles were not successful either. 
Next, the EphA2 siRNA sequences that worked very well for transient knockdown were 
used to create shRNA sequences. After packing these sequences in lentiviruses, they were 
used to transfect cells. Again, these did not produce the desired stable EphA2 knockdown 
result. Ultimately, the custom made lentivirus #3 (described in the Materials and 
Methods) containing the EphA2 shRNA construct obtained using Invitrogen’s RNAi 
Designer ended up being the only vector that led to a significant and stable depletion of 
EphA2 at both the protein and mRNA levels in two metastatic breast cancer cell lines 
(Figure 6). The point of describing the various attempts that were made to achieve a 
stable knockdown of EphA2 is metastatic breast cancer cell lines is to convey the 
message that the in vitro and in vivo results based on stable EphA2 receptor knockdown 
would have been strengthened if they could have been repeated using an additional 
shRNA construct, but this turned out to be unachievable with the numerous methods 
tested to date. Therefore, the experiments were carried out with the use of only one 
lentiviral vector plasmid containing an EphA2 encoding shRNA sequence, LV3.  
 EphA2 has been implicated to play a role in migration in the head and neck 
carcinoma cell line, HN5, and in the A431 cell line (100). Not only is EphA2 expression 
upregulated by EGF-activated EGFR, but treatment of the aforementioned cell lines with 
EphA2-targeting siRNA resulted in an inhibition of migration as determined by wound 
healing assays (100). In addition, EGF has been shown to induce migration of MDA-MB-
231 breast cancer cells, but this finding did not include EphA2 as a part of the 
mechanism. This EGF-induced migration of metastatic breast cancer cells was confirmed 
and expanded upon by the work done in this thesis in the MDA-MB-231 Luc and BT549 
cells (Figure 7). The use of EphA2 siRNA in these migration experiments revealed that 
EphA2 is most likely a participant in this EGF-activated EGFR migratory pathway and 
other studies using alternative cancer models have shown this to be the case as well (100, 
101). The hypothesis that EphA2 plays a role in the metastatic process by affecting the 
migratory ability of breast cancer cells was first confirmed by using EphA2 siRNA to 
reveal a reduction in EGF-induced migration. Lentiviral transduction of BT549 and 
MDA-MB-231 Luc cells with either the non-targeting or EphA2-targeting constructs was 
performed to show that the breast cancer cell lines with stably reduced EphA2 still 
showed a reduction in EGF-induced migration, thus confirming the results obtained with 
transient silencing of EphA2. The mechanism underlying this reduced migration is still 
being elucidated, but it has been demonstrated that activated EGFR phosphorylates Akt 
which serine phosphorylates EphA2, leading to the formation of a protein complex, 
subsequent activation of Rac1, and initiation of migration (102, 103).  
 To continue investigating the effects of stable EphA2 receptor knockdown, 
anchorage-independent growth assays were conducted to see if EphA2 might play a role 
in the ability of breast cancer cells to grow independent of attachment to plastic (Figure 
8). Normal epithelial cells usually cannot survive detachment from the extracellular 
matrix (101, 104). Once detached, these cells undergo programmed cell death called 
anoikis (104). However, metastatic cancer cells have acquired the ability to overcome cell 
death as a result of ECM detachment and can survive longer in suspension (104). This 
gives cancer cells the ability to survive after dissociation from the primary tumor where 
they now have a high likelihood of metastasizing (101, 104). Suspension of MDA-MB-
231 Luc LVNC and MDA-MB-231 Luc LV3 cells in agar containing either 10% FBS or 
1% FBS did not reveal any anchorage independent growth differences between the cell 
lines. This result suggests that EphA2 does not play a role in anchorage independent 
growth of these cells. One study suggests that EphA2 expression is restricted to adherent 
cells and is actually decreased upon detachment from plastic in vitro (101). Therefore, it 
is possible that stably reduced EphA2 expression does not affect the anchorage 
independent growth of metastatic breast cancer cells and the downregulation after cell 
detachment seen in this previous study may be an explanation as to why there is no 
difference between the MDA-MB-231 Luc LVNC and MDA-MB-231 Luc LV3 cell 
lines.  
 Another use for the stable knockdown cell lines is to elucidate the effect that 
EphA2 may have on tumorigenicity in the mammary fat pad of mice. Delivery of siRNA 
to mammary fat pad tumors is one strategy to study how receptor knockdown influences 
tumor growth and other properties after tumor establishment, but it cannot indicate the 
role that reduced EphA2 plays in the actual tumor establishment process. Athymic female 
nude mice that had been injected in the mammary fat pad with MDA-MB-231 Luc LV3 
showed decreased tumor growth when compared to the mice injected with the MDA-MB-
231 Luc LVNC cells (Figure 9). This experiment was repeated and the resultant data 
confirmed the findings these initial findings. It appears that EphA2 did affect the ability 
to form tumors in the mammary fat pad although it is not clear exactly what is happening 
here. Protein analysis by western blot and densitometry confirmed that the LV3 
mammary fat pad tumors had decreased EphA2 protein levels and had a slight reduction 
in EGFR protein levels as well (Figure 10). However, given that EphA2 does not play a 
well-characterized role in cell growth and proliferation in MDA-MB-231 cells (101), it is 
unknown exactly how proliferation is being affected. EphA2 may not be affecting tumor 
growth directly, however, given the established role of EGFR in promoting cancer cell 
proliferation, it is possible that the decrease in tumorigenicity is actually an indirect effect 
of EphA2 somehow reducing the EGFR levels in the tumor cells (101). However, 
staining for proliferation and apoptosis markers (Ki-67 and cleaved caspase-3) did not 
show any differences between MDA-MB-231 Luc LVNC tumor sections and MDA-MB-
231 Luc LV3 tumor sections. These results could be due to the relatively small difference 
in tumor sizes between the LVNC and LV3 groups, or it could be due to inadequate 
sampling of slides. Staining tumor tissue sections for CD31 revealed a significant 
decrease in the density of microvessels in the LV3 tumors compared to the LVNC tumors 
(Figure 11), but in vitro studies assaying for VEGF concentrations in the EphA2 reduced 
cells did not reveal a difference in concentration compared to the control cells. However, 
other cytokines regulating angiogenesis may be altered. For example, it is possible that 
EphA2 receptor depletion may have more of an effect on matrix metalloproteinases, 
MMPs, which are also involved in the angiogenic process (105).  The trend seen in 
decreased EphA2 and decreased microvascular density in tumor tissue remains unclear. A 
more comprehensive investigation, such as expression profiling of RNA from tumor 
tissues, might provide insight into why the tumors with lower EphA2 expression grew 
more slowly than the control counterparts.  
 Furthermore, stable knockdown of EphA2 was required to understand the role this 
receptor plays in the development of metastases in vivo. Intravenous injection of the 
MDA-MB-231 Luc LVNC or LV3 cells into mice revealed a correlation between reduced 
EphA2 and a decrease in the number of mice that developed lung metastases (Figure 12). 
This suggests that EphA2 plays a role in the ability of cancer cells to establish secondary 
tumors once they have dislodged from the primary tumor, entered circulation, and 
arrested in the capillary beds of other tissues within the body. Reducing the expression of 
EphA2 in EphA2-expressing breast carcinomas might be one way to reduce the incidence 
of metastasis.  
The results of the in vitro and in vivo experiments involving MDA-MB-231 Luc 
and BT549 cells with stably reduced EphA2 clearly show that there is a trend between 
diminished receptor levels, decreased migration, decreased tumorigenicity, decreased 
vessel formation, and reduced development of lung metastases, although, the exact 
cellular mechanics behind these findings are still unclear. Further work needs to be done 
to strengthen the current results and to elucidate the pathways involved. 
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Specific Aim II: Utilization of Targeted siRNA to Study the Effect of 
Transient EphA2 Reduction In vitro and In vivo  
 
Introduction 
 Since its discovery, EphA2 has been found to be upregulated during specific 
developmental processes and also during the process of mammary branching 
morphogenesis in the pubescent female breast (43, 47, 48, 51). However, aside from 
these two key periods of upregulation, EphA2 expression is low and limited to epithelial 
tissues (53, 54). Interestingly, this normal pattern of EphA2 expression is disrupted 
during the development of aggressive carcinomas such as those of the prostate, pancreas, 
and ovaries, where EphA2 is aberrantly regulated which results in receptor 
overexpression (63, 65, 66). Similar to the aforementioned types of cancer, EphA2 
overexpression is also consistently found in the more aggressive and metastatic breast 
cancers (77). Investigation into the role of EphA2 in the process of malignant 
transformation of normal breast epithelium has identified it as an oncoprotein whose 
overexpression can single-handedly promote normal cell transformation to a cancerous 
and subsequently metastatic state (50, 53). Furthermore, molecules whose aberrant 
regulation or expression is classically associated with cancer promotion have been found 
to regulate EphA2. Such molecules include the estrogen hormone, E-cadherin, and 
LMW-PTP. Indeed, dysregulation of these molecules contributes to the overexpression 
and cancer-promoting functions of EphA2 (53, 59, 75, 76, 84).  
 The overexpression of EphA2 exhibited in aggressive forms of various cancers 
with high metastatic potential has made it the focus of investigations aiming to define and 
target novel molecules that have potential therapeutic significance (106). Small-
interfering ribonucleic acid (siRNA) that targets EphA2 mRNA to transiently reduce 
protein levels was shown to attenuate pancreatic tumor growth in xenograft models (64). 
Furthermore, EphA2-targeting siRNA delivered in 1,2-Dioleoyl-sn-glycero-3-
phosphatidylcholine (DOPC) neutral liposomes had a similar negative affect on tumor 
growth in ovarian cancer studies (95, 107). In breast cancer, adenoviral vectors 
constructed to express the EphA2 ligand, ephrinA1, were introduced to breast cancer cell 
lines and demonstrated reduced tumorigenic potential after EphA2 receptor depletion 
(62). In addition, ectopic overexpression of EphA2 could be reversed by using an EphA2-
targeting antibody, which resulted in an increase in sensitivity to chemotherapeutic agents 
(108). However, while various methods have been utilized in breast cancer studies to 
reduce EphA2 levels, the siRNA transient silencing approach and its ability to affect 
indicators of tumorigenic and metastatic potential in vitro and in vivo hasn’t been 
extensively studied. 
 The goal of Specific Aim II is to elucidate the affect of EphA2-targeting siRNA in 
vitro and in vivo with the intention of more fully understanding the biology behind this 
receptor’s mechanism of action and possibly identifying a novel therapy for the treatment 
of metastatic breast cancer.  A variety of breast cancer cell lines were analyzed for 
EphA2 protein expression levels and a few specific, overexpressing lines were chosen for 
use in this study. Initial experiments revealed the efficacy of different EphA2-targeting 
siRNA’s in successfully reducing receptor protein levels. The optimal siRNA constructs 
were then used to treat cells prior to conducting various in vitro experiments such as 
migration assays, proliferation assays, and growth factor release assays, all of which 
would aid in determining the effect of EphA2 protein reduction on metastatic potential. In 
vivo studies were carried out by monitoring the effect of treating established mammary 
fat pad tumors with EphA2-targeting siRNA delivered in either DOPC liposomes or 
attached to chitosan nanoparticles. Tumor volume and weights were recorded and post-
treatment analysis of tumor tissue included an evaluation of EphA2 protein levels, tumor 
cell proliferation, and microvascular density.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results: In vitro Studies  
 
Demonstration of EphA2 Expression at the Protein and mRNA Levels in a Variety 
of Breast Cancer Cell Lines 
 Protein isolated from a panel of breast cancer cell lines, with varying degrees of 
aggressiveness and metastatic potential, was subjected to western blot analysis to reveal 
differences in the levels of EphA2 protein expression within the various lines (Figure 
13a). Furthermore, RNA isolated from this same panel of breast cancer cell lines was 
analyzed by qPCR to quantify levels of EphA2 mRNA (Figure 13b). The breast cancer 
cell lines with the highest EphA2 protein levels had correlating mRNA levels, and 
according to the breast cancer subtype classification system proposed by Neve et al, the 
majority of those cell lines with robust EphA2 expression are also of the basal subtype 
(8). This confirms and establishes reports that have found a correlation between ER-
negative, basal subtype breast cancers and EphA2 overexpression (7, 26, 33, 75). As 
previously mentioned, the majority of breast cancer-related deaths result from the disease 
developing metastatic capabilities and causing complications at distant, secondary sites 
(3). Based on the expression data collected and the knowledge that metastasis is a serious 
clinical challenge, the MDA-MB-231, HCC1954, and BT549 cell lines were chosen to be 
the chief cell lines used in my studies due to their relative aggressiveness and high 
EphA2 expression (89).  
   
 
 
 
  
 
 
 
 
 
Figure 13. EphA2 Protein and mRNA Expression Levels 
Western blot analysis of protein lysates collected from twelve breast cancer cell lines 
and probed with an anti-Eck/EphA2 monoclonal antibody. The separated protein 
lysates were also probed with an anti-actin antibody to ensure equal protein loading. 
High EphA2 protein levels were shown to be expressed by a majority of the basal 
subtype breast cancer cell lines. This unpublished data was provided by a previous 
member of the lab. (B) Total RNA was extracted from the same twelve breast cancer 
cell lines and used to carry out quantitative PCR analysis. EphA2 mRNA levels were 
elevated in the same cell lines that had elevated EphA2 protein levels.  
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Use of EphA2-Targeting siRNA to Transiently Reduce Protein Levels in the MDA-
MB-231, HCC1954, and BT549 Cell Lines 
Small-interfering RNA’s are double-stranded RNA’s that are normally 20-25 nucleotides 
in length. The two strands are hybridized in such a way that there is a single stranded 
over-hang at either 3’ end. Transfection reagents make the cell membrane permeable so 
that siRNA can enter. Once inside the cell, the siRNA is incorporated into a complex 
called a RNA-Induced Silencing Complex (RISC) that has endonuclease activity. The 
siRNA is unwound and directs the entire complex to a complementary messenger RNA 
(mRNA) to which the complex binds, cleaves, and subsequently destroys (109, 110). 
Two siRNA constructs purchased from Ambion (Applied Biosystems) that target EphA2 
mRNA were shown to work effectively in various cell lines to transiently reduce EphA2 
protein levels. These two siRNA constructs were used to treat the MDA-MB-231 Luc 
(Figure 14a), HCC1954 (Figure 14b), and BT549 (Figure 14c) cell lines to achieve 
successful transient knockdown. MDA-MB-231 Luc cells treated with the targeting 
siRNA’s exhibited an almost complete knockdown of EphA2 protein, with HCC1954 and 
BT549 cells achieving similarly high levels of protein reduction.  
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 14. siRNA-Mediated Transient Reduction of EphA2 Protein Levels 
Lanes are designated as one of the following: U. Untreated cells HiP. Hiperfect 
transfection reagent added to cells NC. Non-targeting siRNA construct added to cells in 
addition to Hiperfect transfection reagent T1. Cells treated with EphA2-targeting siRNA 
#1 (146) plus Hiperfect transfection reagent T2. Cells treated with EphA2-targeting 
siRNA #2 (242) plus Hiperfect transfection reagent. (A) MDA-MB-231 Luc cells 
revealed successful EphA2 transient knockdown after treatment with the targeting siRNA 
constructs in comparison to treatment with the non-targeting siRNA construct. (B) HCC 
1954 cells revealed successful EphA2 transient knockdown after treatment with the 
targeting siRNA constructs in comparison to treatment with the non-targeting siRNA 
construct. (C) BT549 cells revealed successful EphA2 transient knockdown after 
treatment with the targeting siRNA constructs in comparison to treatment with the non-
targeting siRNA construct. 
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siRNA-Mediated Transient Reduction of EphA2 Protein Levels 
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Cells with Transiently Reduced EphA2 Protein Levels Exhibited a Decrease in 
Migratory Ability Towards Chemoattractants 
The migratory ability of breast cancer cells is important because it allows for progression 
to an invasive and metastatic state (111). In response to 50ng/ml EGF, MDA-MB-231 
Luc and BT549 cells left untreated, treated with the Hiperfect transfection reagent alone, 
or treated with non-targeting siRNA showed greater migration than those cells with 
transiently reduced EphA2 (Figure 15a,b). HCC1954 cells showed modest differences in 
migration when comparing control cells with EphA2-reduced cells. This subtleness could 
be due to the amplification of HER2/neu which could work through other pathways to 
stimulate migration, overcoming the effect of EphA2 depletion on migration towards 
EGF in this cell line (results not shown).  
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Transient EphA2 Reduction Attenuates Migration Towards 
Chemoattractants 
(A) MDA-MB231 Luc cells were either left untreated, treated with the Hiperfect 
transfection reagent alone, treated with non-targeting siRNA, or treated with one of two 
EphA2-targeting siRNA. Cells were then collected, suspended in serum-free media, and 
placed in the upper portion of a transwell chamber. The lower portion contained either 
0.1% BSA in medium or 50ng/ml EGF in medium. Cells were incubated and allowed to 
migrate for 6 hours after which they were fixed, stained, and migrated cells were 
quantified. Cells that had been treated with the EphA2-targeting siRNA showed 
attenuated migration in comparison to the various controls. Application of the Student’s 
t-test found this data to be statistically significant when comparing migration of the 
knockdown cell lines towards EGF and the negative control cell line towards EGF. The 
p-value was 0.02 for T1 and 0.002 for T2. (B) BT549 cells were either left untreated, 
treated with the Hiperfect transfection reagent alone, treated with non-targeting siRNA, 
or treated with one of two EphA2-targeting siRNA. Cells were then collected, suspended 
in serum-free media, and placed in the upper portion of a transwell chamber. The lower 
portion contained either 0.1% BSA in medium or 50ng/ml EGF in medium. Cells were 
incubated and allowed to migrate for 6 hours after which they were fixed, stained, and 
migrated cells were quantified. Cells that had been treated with the EphA2-targeting 
siRNA showed attenuated migration in comparison to the various controls. Application of 
the Student’s t-test found this data to be statistically significant when comparing 
migration of the knockdown cell lines towards EGF and the negative control cell line 
towards EGF. The p-value was 0.0004 for T1 and 0.0002 for T2. 
Figure 15 
Transient EphA2 Reduction Attenuates Migration Towards Chemoattractant 
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Investigation into the Relationship between EphA2 and EGFR in Promotion of 
Cancer Cell Migration 
The EphA2-EGFR relationship has been explored in other cancer cell lines. EGFR 
activation by its ligand was shown to induce EphA2 expression in the human head and 
neck carcinoma cell line, HN5, and in a cell line derived from a human epidermoid 
carcinoma in the vulva, A431 (100). Further studies have revealed that EphA2 and EGFR 
colocalize on the plasma membrane of these cells and can be co-immunoprecipitated, 
providing evidence that these two receptors physically interact (100). Furthermore, 
EphA2 knockdown reduced cell migration towards EGF, suggesting that the EphA2 
receptor plays a role in EGF-stimulated motility in these cells (100). We sought to find 
out if the same relationship existed in breast cancer cell lines since EphA2 depletion also 
leads to reduced EGF-stimulated migration in our cells. Western blot analysis revealed 
that siRNA-mediated transient reduction of EphA2 in the MDA-MB-231 Luc and BT20 
breast cancer cell lines led to reduced EGFR receptor expression (Figure 16a). Total 
RNA was extracted from the same twelve breast cancer cell lines used to analyze EphA2 
mRNA levels and used to carry out quantitative PCR analysis to look at EGFR mRNA 
levels in these cell lines (Figure 16e). The BT20 cell line was used because it not only 
expresses EphA2, but it also has EGFR amplification. The basis for using this cell line 
was to ensure that there is ample EGFR for the EphA2 to interact with. Larsen et al. also 
reported that the EphA2 gene is a downstream transcriptional target of the EGF-activated 
EGFR pathway (100). However, when EGFR was transiently reduced in these same cell 
lines EphA2 receptor levels appeared unaffected (Figure 16c,d). Possible explanations for 
this will be in the discussion section.  
  
 
Figure 16. Transiently Reducing EphA2 Levels Leads to a Reduction in EGFR 
Expression 
MDA-MB-231 Luc and BT20 cells were both treated with either EphA2 targeting siRNA 
(T1 and T2) or EGFR targeting siRNA (E1, E2, and E3) to transiently reduce levels of 
the corresponding protein. Membranes were then probed with EphA2 and EGFR 
antibodies to reveal the quantities of the receptors in the protein lysates. (A) MDA-MB-
231 Luc cells treated with EphA2 siRNA (top blot) showed reduced levels of EphA2. 
Subsequent probing for EGFR on the same membrane revealed a reduction in EGFR 
protein levels also (middle blot). Actin was used as the control to ensure that the protein 
samples were loaded equally. (B) MDA-MB-231 Luc cells were treated with EGFR 
targeting siRNA that successfully reduced the EGFR protein levels (upper, right). When 
probed for EphA2, no differences in EphA2 protein levels were found after treatment 
with EGFR targeting siRNA (upper, left). Actin was used as the control to ensure that the 
protein samples were loaded equally. (C) EGFR targeting siRNA successfully reduced 
EGFR protein levels in BT20 cells. (D) EphA2 protein levels were unaffected by the 
transiently reduced levels of EGFR in BT20 cells. Actin was used as the control in both 
C and D to ensure equal protein loading. (E) Relative quantities of EGFR and EphA2 
mRNA in a panel of breast cancer cell lines.  
 
 
Figure 16 
Transiently Reducing EphA2 Levels Leads to a Reduction in EGFR Expression 
(A) MDA-MB-231 Luc: EphA2 siRNA          (B) MDA-MB-231 Luc: EGFR siRNA 
 
 
 
 
 
  
 
(C) BT20: EGFR siRNA    (D) BT20: EGFR siRNA 
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EphA2 and EGFR Co-localize at the Plasma Membrane of MDA-MB-231 Luc Cells 
Having seen that there is a relationship between EphA2 and EGFR protein levels when 
EphA2 is transiently reduced, it was hypothesized that EphA2 and EGFR may colocalize 
at the plasma membrane and could potentially interact within a complex. EphA2 and 
EGFR were found to be co-localized in the HN5 and A431 cell lines, evidence that 
further motivated investigation into this hypothesis (100). To visualize the location of 
EphA2 and EGFR in MDA-MB-231 Luc cells, immunocytochemical fluorescent staining 
was carried out (Figure 17a). Images revealed that EphA2 and EGFR do appear to 
colocalize in this cell line. To confirm and enhance the validity of this finding, cells were 
also stained so that they could be imaged using a confocal microscope which enables the 
cells to be reconstructed in three dimensions (Figure 17b). The technique of Z-stacking 
was employed which allows different planes at various depths within the cell to be 
visualized (Figure 17c). This represents a way to see if the cellular EGFR an EphA2 co-
localization at the plasma membrane is consistent throughout the cell, and we found that 
it is. These fluorescent and confocal images revealing EphA2 and EGFR co-localization 
led us to propose that the two receptors could possibly be physically interacting.  
 
 
 
 
 
 
 
  
 
 
Figure 17. Demonstration of EphA2 and EGFR Co-localization 
(A) MDA-MB-231 Luc and MCF7 (not shown) cells were stained for fluorescent 
imaging. MCF7 served as the negative control for the specificity of reagents seeing as 
they do not express EphA2 or EGFR. EphA2 and EGFR staining can be visualized on the 
plasma membrane, specifically in areas of membrane ruffling, and distributed throughout 
the cytoplasm. MCF7 cells have little to no endogenous expression of EphA2 and EGFR 
and, when stained for these two receptors, no positive staining occurred. (B) Confocal 
imaging of MDA-MB-231 Luc cells revealed co-localization of EphA2 (green, top right) 
and EGFR (red, top left). Nuclear staining is shown in blue (bottom left) and the merged 
image is shown in the bottom right square. (C) This image represents one of the Z-stack 
images showing EphA2 and EGFR co-localization. EGFR is shown in green (top left), 
EphA2 is shown in red (top right), nuclear staining is shown in blue (bottom left), and the 
merged image is shown in the bottom right square. Confocal and Z-stack images were 
also compared to stained MCF7 cells which did not show positive expression of EphA2 
and EGFR.  
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Demonstration of EphA2 and EGFR Co-localization  
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Immunoprecipitation of EphA2 from MDA-MB-231 Luc Cell Protein Lysates Did 
Not Pull Down of EGFR After Stimulation with EGF 
Western blot analyses had previously revealed that EGFR protein levels are reduced 
when cells are treated with EphA2-targeting siRNA. This led to the proposal that EGFR 
and EphA2 may co-localize at the plasma membrane and interact within a complex. 
Disruption of the physical interaction between EGFR and EphA2 due to transient 
reduction of EphA2 levels with siRNA might destabilize EGFR at the membrane leading 
to subsequent internalization and degradation of the receptor. To investigate whether or 
not EphA2 and EGFR complex, co-immunoprecipitation assays were completed. Equal 
amounts of protein from MDA-MB-231 Luc cells that were either stimulated with 
50ng/ml EGF (+) or left un-stimulated (-) were immunoprecipitated with 5µg of mouse 
anti-Eck antibody. Agarose beads were then used to precipitate any immunocomplexes. 
Western blot analysis revealed that immunoprecipitation of EphA2 by an anti-EphA2 
antibody does not lead to the pull down of EGFR in these breast cancer cells (Figure 
18a,b).  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 18. Immunoprecipitation of EphA2 Does Not Lead to EGFR Pull Down 
(A) MDA-MB-231 Luc cell pre-cleared protein lysates were immunoprecipitated with 
either a negative control mouse IgG antibody or anti-EphA2 antibody. Subsequent 
western blot analysis revealed that EGFR had not been pulled down. 20µg of the original, 
non-immunoprecipitated protein lysate was set aside as a control to ensure that EGFR 
was present. (B) The membrane was stripped and reblotted for EphA2 to ensure that it 
had been immunoprecipitated by the anti-EphA2 antibody. EphA2 was both present in 
the original whole lysate and was also successfully precipitated out. Results are 
representative of multiple experiments.  
 
 
 
 
 
 
 
Figure 18 
Immunoprecipitation of EphA2 Does Not Lead to EGFR Pull Down 
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Comparison of Vascular Endothelial Growth Factor Release in Cells Treated with 
Non-Targeting siRNA and EphA2-Targeting siRNA 
Angiogenesis is one of the key processes required for successful tumor establishment and 
growth (67). Recruitment of preexisting vessels and development of new vessels within 
the tumor hinges upon proper expression and function of pro-angiogenic growth factors 
and their receptors (67, 112, 113). Eph receptors and their ligands have been implicated 
to be involved in the development of embryonic vasculature (114). Recently, studies have 
revealed that EphA2 is important in the tumor microenvironment in order for 
angiogenesis to occur for progression to metastasis (113). Furthermore, endothelial cells 
lacking EphA2 do not participate in vascular assembly, nor do they participate in vascular 
migration (115). Although EphA2 appears to be associated with the process of vessel 
formation and growth during tumorigenesis, the specific mechanism behind this 
association remains vague. Release of the vascular endothelial growth factor (VEGF) was 
measured in breast cancer cell lines with reduced EphA2 to establish whether the receptor 
protein reduction correlated with a decrease in VEGF release. Preliminary data suggested 
that transiently reducing the EphA2 levels in MDA-MB-231 cells produced a significant 
decrease in VEGF release into the supernatant (Figure 19a). However, repetition of this 
experiment did not reproducibly find a strong correlation between EphA2 receptor 
depletion and decreased VEGF release in the MDA-MB-231 cell line, HCC1954 cell line, 
nor the BT549 cell line (Figure 19b,c). 
 
 
 
  
 
 
 
Figure 19. VEGF Release in Metastatic Breast Cancer Cell Lines with Attenuated 
Levels of EphA2 Receptor Protein Levels 
(A) ELISA analysis of supernatant collected from MDA-MB-231 cells after treatment 
with EphA2-targeting siRNA revealed lower levels of released VEGF compared to cells 
treated with the non-targeting siRNA or with the transfection reagent alone (preliminary 
result). This data was found to be statistically significant using the GraphPad Prism 5 
software. (B) ELISA analysis of supernatant collected from HCC1954 cells after 
treatment with EphA2-targeting siRNA revealed mildly lower levels of released VEGF 
compared to cells treated with the non-targeting siRNA or with the transfection reagent 
alone. These data were not statistically significant. (C) ELISA analysis of supernatant 
collected from BT549 cells after treatment with EphA2-targeting siRNA revealed no 
reduction in released VEGF compared to cells treated with the non-targeting siRNA or 
with the transfection reagent alone. 
 
 
 
 
 
 
Figure 19  
VEGF Release in Metastatic Breast Cancer Cell Lines with Attenuated Levels of 
EphA2 Receptor Protein Levels 
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Results: In vivo Studies 
 
Having accumulated some data supporting the hypothesis that transiently depleted 
EphA2 levels will negatively affect in vitro assays that indicate tumor cell metastatic 
capability, we wanted to see if reducing EphA2 levels with siRNA would have any effect 
on established mammary fat pad tumor growth and persistence in female athymic nude 
mice. 
Since its discovery, the use of the RNA interference (RNAi) pathway as a method of 
silencing the expression of specific genes has continually helped to advance our 
understanding of basic biology and disease states (116). Introducing siRNA into a cell 
results in its uptake and incorporation into the RISC (RNA-induced silencing complex) 
protein complex which recognizes complementary mRNA in the cytoplasm and destroys 
them (116). While RNAi is a natural part of eukaryotic processes, artificially synthesizing 
and efficiently delivering siRNA to its specific target in a live animal model has proven 
to be a challenge (116).  
However, there are two methods of siRNA delivery that have been reported to be 
successful and that we employed to deliver non-targeting or EphA2-targeting siRNA to 
the mammary fat pad tumors in our experiments. The first are DOPC liposomes. DOPC is 
a natural lipid used to synthesize liposomes. siRNA can be packaged within DOPC 
liposomes and injected for intratumoral delivery (95, 107). We also used chitosan 
nanoparticles as a route of siRNA delivery because, among other things, they are unlikely 
to elicit an immune response and they are nontoxic (117). Furthermore, nanoparticles 
have been shown to be more efficient than DOPC liposomes because they have a positive 
charge that allows for increased transport across the cell membrane (118). Additionally, 
Han et al. showed that certain ligands can be attached to the nanoparticles in order to 
specifically target markers found on the surface of tumor cells (118). In their case, they 
used the RGD ligand (Arg-Gly-Asp) which targeted the αvβ3 integrin expressed on 
ovarian cancer cells (118). This technique could possible be applied to specifically target 
EphA2 on the surface of breast cancer cells. In addition to delivering siRNA (either 
EphA2 targeting or non-targeting), we also designated some groups to be treated with 
chemotherapy as well. In total we had ten groups: PBS Control, PBS + Paclitaxel, DOPC 
Control siRNA, DOPC Control siRNA + Paclitaxel, DOPC EphA2 siRNA, DOPC 
EphA2 siRNA + Paclitaxel, Nanoparticle Control siRNA, Nanoparticle Control siRNA + 
Paclitaxel, Nanoparticle EphA2 siRNA, Nanoparticle EphA2 siRNA + Paclitaxel. Those 
mice that were also receiving chemotherapy were injected i.p. once weekly with 24mg/kg 
of Paclitaxel. This dose was established to be effective, yet non-toxic, in preliminary 
studies carried out by previous laboratory members.   
Previous research has shown that fluorescently labeled DOPC liposomes injected i.v. 
into mice were detected in mammary fat pad tumors of the MDA-MB-231 breast cancer 
cell line (Price et al., unpublished data). This observation and the findings with a 
melanoma xenograft model supported the feasibility of systemic administration to deliver 
siRNA to solid tumors (119) (Figure 20). 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 20. Successful Delivery of Fluorescently Labeled DOPC Liposomes to MFP 
Tumors 
A cross section of a MDA-MB-231 Luc established mammary fat pad tumor collected 6 
hours post i.v. injection of fluorescently labeled DOPC liposomes. CD31 staining is 
represented by the green color, tumor cell nuclei staining is represented by the blue color, 
and the fluorescently tagged DOPC liposomes are represented by the red color.  
 
 
 
 
 
 
 
 
  
 
 
 
Figure 20 
Successful Delivery of Fluorescently Labeled DOPC Liposomes to MFP Tumors 
 
 
 
 
 
 
 
 
 
 
(Price et al., unpublished data) 
 
 
 
 
 
Delivery of EphA2-Targeting siRNA by DOPC Liposomes or Chitosan 
Nanoparticles had No Significant Impact on Tumor Growth to the Corresponding 
Control 
MDA-MB-231 Luc cells were injected into the mammary fat pad of female nude mice 
and allowed to grow. Once the tumors became palpable, they were measured twice a 
week and the volumes were calculated. Tumor growth for each group was monitored over 
time and recorded as volume vs. time (Figure 21a,b,c,d). Additionally, the dates and 
numbers of mice sacrificed were noted and analyzed by means of a survival curve (data 
not shown). Although there was no significant difference in tumor sizes, the mice treated 
with EphA2-targeting siRNA nanoparticles without paclitaxel treatment did show a 
modest decrease in tumor growth and had a longer mean survival time than the 
comparative control (Figure 21c). The dose of paclitaxel used in these experiments had 
previously been shown to control tumor growth and be non-toxic, but it was not effective 
in this experiment. Although monitoring tumor growth and animal survival are useful 
ways to analyze the effect of EphA2 reduction in MFP tumors in vivo, a more direct 
readout of the effect of EphA2-targeting siRNA was measured by analyzing EphA2 
protein content in the tumor tissues.  
 
 
 
 
 
 
  
 
 
 
Figure 21. Tumor Growth in siRNA Treated Animals 
Mammary fat pad tumors were monitored and their lengths and widths were recorded as 
they grew. The tumor volumes were calculated and plotted on a graph versus time. Day 0 
represents the day the cells were first injected into the mammary fat pad of the mice and 
all subsequent days represent the number of days post-injection. Tumor volumes of a 
particular experimental group receiving EphA2-targeting siRNA were compared to the 
corresponding control group receiving the non-targeting siRNA and the PBS control 
group. Tumor growth can be seen in the DOPC liposome group (A), the DOPC liposome 
+ Paclitaxel group (B), the nanoparticle group (C), and the nanoparticle + Paclitaxel 
group (D). According to these graphs, there is no significant difference in tumor growth 
compared to the respective controls in any of the groups, however, the mice treated with 
EphA2-targeting nanoparticles without Paclitaxel revealed decreased tumor growth 
compared to the controls. The p-value for this group was 0.5. Arrows indicate when 
treatment was initiated, which was 21 days after MFP injection. 
 
 
 
 
Figure 21 
Tumor Growth in siRNA Treated Animals 
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Analysis of Tumor Protein Lysate Revealed EphA2 Protein Levels Parallel the 
Trend Seen in Tumor Growth between the Various Experimental Groups 
At the time of animal sacrifice, tumor tissue was collected for protein analysis. Snap 
frozen tumor tissue was lysed, purified, and sampled for EphA2 protein quantities. 
Western blot analysis revealed that all tumors without paclitaxel treatment had uniformly 
strong EphA2 expression, the exception being those samples collected from the group 
treated with EphA2-targeting siRNA chitosan nanoparticles (Figure 22a). This group had 
the lowest amounts of EphA2 expression and also had decreased tumor growth over time. 
Further densitometry analysis of EphA2 protein levels confirmed a slight reduction in the 
tumor tissue taken from those tumors where mice had been treated with EphA2-targeting 
chitosan nanoparticles in comparison their respective control (Figure 22b). Actin levels 
were blotted for as a control to ensure equal protein loading. Due to the lack of 
significant differences amongst those groups that also received concomitant 
chemotherapy, we only analyzed tumor EphA2 protein levels in the groups treated with 
the nanoparticles and paclitaxel (Figure 22c). In these particular groups, no EphA2 
protein reduction was seen, and in fact, EphA2 levels were higher in these tissue lysates 
when compared to any of the DOPC liposome and nanoparticle treated groups that didn’t 
receive paclitaxel. All protein lysates samples were also analyzed for levels of EGFR 
protein, but no correlation or trend was found from this protein analysis.   
 
 
 
 
 
  
 
Figure 22. EphA2 and EGFR Protein Levels in Animal Tumor Tissue Treated with 
PBS, DOPC Liposomes, and Chitosan Nanoparticles 
(A) Western blot analysis of protein isolated from the mammary fat pad tumors collected 
from the mice treated with PBS, DOPC liposomes containing either EphA2-targeting 
siRNA or non-targeting siRNA, or chitosan nanoparticles containing either EphA2-
targeting siRNA or non-targeting siRNA revealed no obvious attenuation in EphA2 
protein levels except in the group of tumors where mice were treated with EphA2-
targeting nanoparticles. Immunoblotting for EGFR did not reveal a trend or correlation 
with EphA2 protein levels. Immunoblotting for actin served as the control to ensure that 
equal amounts of protein were loaded. (B) Densitometry of the blot confirmed that 
EphA2 protein levels were lower in the tumors where the mice were treated with EphA2-
targeting nanoparticles in comparison to the corresponding control (left). The EphA2 
protein levels in those mice treated with EphA2-targeting DOPC liposomes were not 
attenuated and were equivalent to the levels seen in the corresponding control (right). (C) 
Protein analysis of tumors that were treated with both EphA2-targeting nanoparticles and 
Paclitaxel showed enhanced EphA2 expression compared to the corresponding control 
(left). Actin was blotted for to ensure equal protein loading amongst samples. 
Densitometry analysis confirmed this enhanced expression (right). 
 
 
Figure 22 
EphA2 and EGFR Protein Levels in Animal Tumor Tissue Treated with PBS, 
DOPC Liposomes, and Chitosan Nanoparticles 
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Discussion: Utilization of Targeted siRNA to Study the Effect of 
Transient EphA2 Reduction In vitro and In vivo 
  
 The goal of Specific Aim II was to utilize EphA2-targeting siRNA to study the 
effect of reduced receptor levels on properties indicating aggressive and metastatic 
behavior in metastatic breast cancer cell lines in vitro and in mammary fat pad tumors in 
vivo. EphA2 overexpression was found in the basal subtype of breast cancers at both the 
protein and mRNA levels. Breast cancer cell lines of the basal subtype are clinically more 
aggressive and are most infamously known for exhibiting the “triple negative” phenotype 
(7, 33). This correlates with data obtained from studies done in other cancer models 
where EphA2 overexpression is found in the more aggressive and metastatic cancer cell 
lines (64, 66, 69).  
 The ability of tumor cells to migrate positively correlates with metastatic potential 
because migration is crucial for tumor cell invasion, a key step in the ability of tumor 
cells to escape from the confines of the primary tumor and enter into circulation (89, 
120). EGFR activation by its ligand, EGF, is one example of a receptor-ligand association 
that is a pertinent part of the migratory capability of tumor cells (100, 120). Larsen et al. 
have shown that EphA2 is a transcriptional target of the activated EGF-EGFR pathway 
and that the two receptors physically interact to induce cell motility (100). Treatment of 
BT549 and MDA-MB-231 Luc cells with EphA2-targeting siRNA resulted in attenuated 
migration towards the EGF chemoattractant (Figure 15). It was therefore hypothesized 
that EphA2 and EGFR physically interact in order to stimulate tumor cell migration in 
breast cancer cells. This hypothesis seemed logical given that a reduction in EphA2 
protein levels might destabilize EGFR at the plasma membrane, leading to increased 
EGFR internalization and degradation (Figure 16). With less EGFR present on the cell 
surface, breast cancer cells would be unable to migrate as efficiently in the presence of 
EGF compared to those cells where EphA2 had not been transiently knocked down. 
However, co-immunoprecipitation studies using protein lysates from either unstimulated 
or EGF-stimulated MDA-MB-231 Luc cells failed to show that precipitation of EphA2 
by an anti-Eck antibody would pull down EGFR (Figure 18). There are several possible 
reasons why this data did not confirm what Larsen et al. had found. Firstly, the A431 cell 
line used by Larsen’s group has significantly higher physiological levels of EGFR than 
the MDA-MB-231 Luc cell line due to EGFR amplification. A quantification of EGFR 
receptor levels found on the cell surface of both of these cell types indicates that the 
EGFR levels on the A431 cells is at least 8 fold higher than the EGFR levels found on the 
surface of MDA-MB-231 Luc cells (121, 122). This receptor amplification may affect the 
co-immunoprecipitation of EphA2 and EGFR. It is possible that although MDA-MB-231 
Luc cells do express EGFR, the endogenous levels are not high enough to exhibit the 
EGFR-EphA2 complex formation by co-immunoprecipitation analysis. Furthermore, the 
MDA-MB-231 Luc cells were stimulated with EGF for 15 minutes before harvesting the 
cells and collecting the protein lysate. The A431 and HN5 cell lines in the work of Larsen 
et al. were stimulated with EGF for 24 hours before carrying out the co-
immunoprecipitation assay. It’s possible that the MDA-MB-231 Luc cells should be 
stimulated with EGF for a longer period of time in order to successfully demonstrate 
EGFR pull down after precipitation of EphA2. This would be something to look into for 
future experiments.  
 While the possible interaction of EGFR and EphA2 within a complex should 
certainly continue to be a focus of investigation, a couple of recent studies have indicated 
that EGFR and EphA2 may both be vital players in the migratory mechanics of breast 
cancer cells without necessarily physically interacting (102, 103). Miao et al. used the 
glioblastoma cell line, U373, to show that EGF-stimulated EGFR results in the activation 
of Akt. When EphA2 is not being stimulated by its own ligand, ephrinA1, it serves as a 
substrate for this EGFR-activated Akt leading to serine phosphorylation of EphA2 (102). 
Additionally, Miao et al. were able to show that inhibiting either the activation of Akt by 
EGFR or the serine phosphorylation of EphA2 by activated Akt resulted in decreased cell 
migration, however, the downstream mechanism leading to migration was not elucidated 
(102). More recently, Hiramoto-Yamaki et al. have produced data using breast cancer 
cells that suggests that in response to EGF stimulation, Ephexin4 binds EphA2 leading to 
RhoG activation and recruitment of ELMO2 and Dock4 to the Ephexin4-EphA2 protein 
complex (103) (Figure 16). This activated complex activates Rac1 and leads to the 
promotion of cell migration (103). They have yet to unveil how EphA2 is being activated 
that is leading to Ephexin4 recruitment, but they suggest it could be the same Akt 
mechanism that was shown to promote cell migration through EphA2 in the glioblastoma 
cells (102, 103). Linking these two mechanisms has recently been the subject of my 
investigations in metastatic breast cancer cell lines as a way to explain how EphA2 is 
involved in the promotion of tumor cell migration. According to this hypothesis, siRNA-
mediated EphA2 reduction would certainly attenuate the migratory ability of breast 
cancer cells by inhibiting the formation of the Ephexin4-EphA2-Elmo2-Dock4 protein 
complex that ultimately activates Rac1 (Figure 16). 
  
 
 
 
 
 
Figure 23. Proposed Mechanism of EphA2’s Role in Rac1 Activation and Cell 
Migration 
The proposed mechanism of EphA2 involvement in cancer cell migration begins with the 
stimulation of EGFR by its ligand EGF. Once activated, EphA2 becomes activated by an 
unknown mechanism. Ephexin4 is recruited to EphA2 the activated complex stimulates 
the RhoG exchange of GDP for GTP so that it is now in the activated state. Activated 
RhoG recruits Elmo2 and Dock4 to the protein complex. This protein complex stimulates 
the Rac1 exchange of GDP for GTP, thus activating it. The entire activated complex 
localizes at points of membrane ruffling to promote cell migration. 
 
 
 
 
 
 
 
Figure 23 
Proposed Mechanism of EphA2’s Role in Rac1 Activation and Cell Migration 
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Whether EGFR and EphA2 are interacting within a complex to promote cell 
migration, or whether Akt is acting as the intermediate between the two receptors, there 
were still other dynamics of the EphA2-EGFR relationship to be explored. EphA2 has 
been shown to be a transcriptional target of EGF-activated EGFR (100). To see if the 
same relationship existed in breast cancer cell lines and to see if the opposite might be 
true (EGFR is a transcriptional target of EphA2), MDA-MB-231 Luc and BT 20 cells 
were treated with either EGFR or EphA2-targeting siRNA. In both cell lines, transient 
reduction of EphA2 led to a decrease in EGFR, but transient reduction of EGFR did not 
lead to a reduction in EphA2 (Figure 16). It’s possible that, even though we cannot detect 
a direct assocation by the co-immunoprecipitation assay, the reduction in EphA2 leads to 
increased EGFR internalization and degradation. It’s also possible that the activated 
EphA2 pathway in cancer cells drives EGFR at the transcriptional level, and a reduction 
of EphA2 attenuates that upregulation. However, this cannot be conclusively determined 
using only siRNA methods; rather, investigating whether EphA2 signaling has an impact 
on EGFR promoter activity would be more indicative whether EphA2 can regulate EGFR 
expression.  
At first it was puzzling to see that EGFR reduction did not lead to decreased 
EphA2 levels, as suggested by work from other groups, but it was then realized that 
MDA-MB-231 Luc and BT20 cells are unique. First, MDA-MB-231 Luc cells have a 
constitutively activated Ras that activates EphA2 transcription (77). If the EGFR pathway 
does lead to EphA2 upregulation, siRNA-mediated reduction of EGFR wouldn’t 
necessarily affect EphA2 in this cell line because the constitutively activated Ras would 
maintain the overexpression of EphA2 independent of EGFR (77). Additionally, BT20 
cells have amplified EGFR. Even with the EGFR-targeting siRNA, the levels of 
endogenous EGFR may be so high that it is not being reduced enough and transcriptional 
upregulation of EphA2 is still occurring (123). In order to clarify what the true 
relationship is between EGFR and EphA2 in breast cancer cells after transient reduction 
of either receptor, it would be prudent to try other metastatic breast cancer cell lines that 
do not possess these unique alterations. Moreover, it is also important to note that 
inhibition of migration after transient reduction of EphA2 using siRNA was not only seen 
with EGF used as a chemoattractant. Cells with transiently reduced EphA2 also showed 
reduced migration towards CXCL12, indicating that while there may be a relationship 
between EGFR and EphA2 that is modulating cancer cell migration, EphA2 also works 
through other pathways to affect migration (Price et al., unpublished). 
Lin et al. has indicated that EphA2 plays a large role in the angiogenic process in 
ovarian cancer and it was thus hypothesized that EphA2 may play a similar role in 
metastatic breast cancers (66). Measuring the concentration of VEGF release in the 
supernatant of cultured cells is one indication of cellular participation in angiogenesis 
because this growth factor has been found to be necessary for the recruitment and 
persistence of intra-tumoral vessels (124). However, although preliminary studies 
revealed that decreased EphA2 expression in MDA-MB-231 cells causes a significant 
diminution in the amount of VEGF released, this result could not be repeated to achieve 
the same level of significant reduction in VEGF release in either the MDA-MB-231 cells 
or two other metastatic breast cancer cell lines (Figure 19). While this data is 
discouraging, it’s possible that quantifying cellular release of VEGF is not the most 
informative way to elucidate the effect of reduced EphA2 expression in the angiogenic 
process in breast cancer cells. Lin et al. focused on examining matrix metalloproteinase 
(MMP) expression in EphA2 overexpressing ovarian carcinomas where they found a 
trend between high EphA2 expression and high MMP expression (124). The expression 
of MMPs in metastatic breast cancer cells in the presence or absence of EphA2 was not 
examined in my study and may be worthwhile to investigate in the future due to their 
established role in the process of angiogenesis (105).  
The conclusion that can be made from the in vivo studies whereby EphA2-
targeting siRNA was delivered either in DOPC liposomes or chitosan nanoparticles with 
or without paclitaxel is that EphA2 siRNA nanoparticle delivery seemed to be superior to 
delivery by DOPC liposomes, but only when delivered alone and not in conjunction with 
chemotherapy (Figures 21). The superiority of nanoparticles to DOPC liposomes in 
successfully delivering siRNA to our mammary fat pad tumors confirms what others have 
found in other cancer models (96, 118). The experiment conclusions were made primarily 
based on the analysis of the tumor tissue protein (Figure 22). EphA2 protein was most 
reduced in the mammary fat pad tumors that had been treated with EphA2-targeting 
siRNA in chitosan nanoparticles and this is also the group that showed a trend towards 
decreased tumor growth. EphA2 did not seem to be reduced in the tumors of the other 
treatment groups and this correlated with a lack of difference in tumor growth between 
treatment groups and control groups. The lack of reduction in EphA2 protein levels seen 
in the majority of the treatment groups could be attributed to a couple of different 
explanations. Firstly, it’s not known if the DOPC liposomes containing the EphA2-
targeting siRNA succeeded in reaching the mammary fat pad tumors. It was assumed that 
they did based on preliminary data revealing fluorescently labeled siRNA in DOPC 
liposomes distributed throughout sections of the tumor tissue (Figure 20). This cannot be 
confirmed for this particular experiment since the siRNA was not tagged this time. 
Assuming the EphA2-targeting siRNA did reach the tumors, this suggests that more 
siRNA needs to be delivered more frequently in order to have a significant impact on 
negative impact on intratumoral EphA2 protein levels and mammary fat pad tumor 
growth. Furthermore, it is not known whether the delivered siRNA had off-target effects.  
 Overall, the reduction of EphA2 after utilization of targeting siRNA reveals a 
negative association between attenuated EphA2 protein levels and indicators of 
aggressive and metastatic tumor cell behavior. Although this trend is quite clear, there is 
much investigation that still needs to done to elucidate the specific mechanisms which are 
associated with EphA2 reduction and decreased metastatic potential.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
- Chapter 5 - 
Summary & Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
 
 The development of any given type of cancer requires genetic and/or epigenetic 
alterations that change the normal function of cells, giving them the ability to evade 
homeostatic mechanisms that normally regulate cell activities (125).  This may lead to 
atypical cellular proliferation and subsequent development of benign or malignant tumor 
formation (85). Tumor formation occurs in nearly every location within the human body 
and proof of this is seen in the high number of newly diagnosed cancer cases each year, 
both nationally and internationally (1). This has led to a worldwide investigation into the 
process of cancer development, establishment, and metastasis (1, 85). Metastasis itself is 
a complex process often involving genetic changes in addition to the original cancer-
initiating mutations (85). These acquired cellular alterations allow tumor cells to invade 
into the surrounding tissue and migrate to the closest vessels where they enter the 
circulation and may establish secondary tumors elsewhere (metastases) (85). The 
importance of tumor cells having the capability to metastasize is that these metastases are 
the primary cause of cancer-related deaths in solid tumors due to the fact that they often 
establish themselves in critical locations such as the lungs, brain, and bones (85).  
 EphA2 has been identified in many cancers to be a receptor tyrosine kinase that is 
overexpressed in the more aggressive forms of the diseases (53, 61). This is true for 
melanomas, ovarian cancer, lung cancer, and prostate cancer (63, 65, 126). It has been 
found to increase the metastatic ability by participating in angiogenesis, migration, 
invasion, and growth in these tumor models (63, 65, 66, 126). Importantly, EphA2 is 
shown to be expressed not only in breast cancer cell lines, but also in clinical tumor 
samples (53). The implication is that studying the biology of EphA2 participation in the 
metastatic breast cancer model may prove to be important clinically as well. Furthermore, 
EphA2 is consistently found to be expressed in the aggressive, triple-negative breast 
cancers which are the most aggressive, the most likely to metastasize, and which have 
limited treatment options due to their lack of molecular targets such as ER and HER2 (7, 
33, 77). Despite the inefficient process of metastasis and the number of hindrances tumor 
cells must overcome in order to successfully metastasize, metastasis is responsible for 
over 90% of human cancer deaths (127). Since breast cancer deaths are included in this 
percentage and because EphA2 is highly overexpressed in metastatic breast cancers, it is 
a prospective target for investigation (127). While studies have been done to establish 
which breast tumors and cell lines express EphA2, little has been done to indicate the role 
that EphA2 plays in these aggressive and metastatic breast cancers. Therefore, it was 
hypothesized that reduced EphA2 receptor levels in metastatic breast cancer cell lines and 
in established mammary fat pad tumors would negatively affect the metastatic tumor cell 
characteristics in vitro and would decrease tumorigenicity and tumor persistence in vivo, 
respectively.  
 Cancer cells are intriguing in that they must acquire several characteristics in 
order to successfully establish a tumor (67). They must both be self-sufficient in their 
production of growth signals, while being insensitive to anti-growth signals (67). They 
must also be able to evade intracellular cell death signals in order to proliferate without 
limits (67). Finally, cancer cells must have a self-sustained angiogenic capability and 
should be characterized by their ability to invade in order to metastasize (67). One way to 
study how EphA2 participates in these processes is to investigate what happens to 
metastatic breast cancer cells when EphA2 expression has been diminished. EphA2-
targeting siRNA and EphA2 shRNA sequences were used to achieve a transient and 
stable knockdown of EphA2 in the MDA-MB-231 Luc cell line, the BT549 cell line, and 
occasionally in the HCC1954 cell line (Figures 6 & 13). These three cell lines represent 
metastatic breast cancer cell lines that overexpress EphA2 at both the protein and mRNA 
levels.  
 Migration assays carried out in the presence or absence of chemoattractants when 
EphA2 expression was either maintained or depleted by siRNA or shRNA revealed that 
metastatic breast cancer cell migration was attenuated in the presence of the 
chemoattractants in cells where EphA2 receptor levels had been reduced (Figures 7 & 
15). The ability of breast cancer cells to migrate is crucial to their ability to metastasize 
because they must be able to move to nearby vessels in order to intravasate and enter the 
circulation (67). These findings indicate that EphA2 is a participant in the acquired ability 
of metastatic breast cancer cells to migrate. Further investigation into the mechanism 
behind this participation has revealed that EGFR and EphA2 co-localize and seem to 
have a non-physical relationship in the promotion of tumor cell migration. Additionally, 
recent data from another group has indicated that the migration mechanism in breast 
cancer cells and other cancer cell types begins with EGFR stimulation by ligand, which 
subsequently results in the serine phosphorylation of EphA2 by Akt (102). This has yet to 
be confirmed by my studies. However, another recent study shows that EphA2 serine 
phosphorylation results in the downstream activation of Rac1 which promotes cell 
migration (103). Recent results that I have obtained reveal decreased Rac1 activation in 
the EphA2 silenced cell lines in the presence of EGF compared to the control cells, which 
showed increased Rac1 activity after EGF stimulation. Although this observation does 
not directly connect the two mechanisms found by Miao et al. and Hiramoto-Yamaki et 
al., it does indirectly link EGF stimulation of EGFR to increased Rac1 activation through 
EphA2. In order to better confirm this hypothesized pathway, it would be helpful to look 
at EphA2 serine phosphorylation in the metastatic breast cancer cell lines in the presence 
or absence of an Akt inhibitor and concurrently, in the presence or absence of EGF 
stimulation. Furthermore, it would be beneficial to confirm the decreased Rac1 activation 
in cells with reduced EphA2 expression by also looking at the effect of EGF stimulation 
in the presence or absence of Akt inhibitors on upstream participants of this proposed 
pathway, such as Ephexin4, in these cells. Unfortunately, antibodies against serine 
phosphorylation in EphA2 and against Ephexin4 are not commercially available and 
these studies could not be completed. 
 The siRNA-mediated and shRNA-mediated EphA2-reduced breast cancer cell 
lines were also used to elucidate the effect that EphA2 has on angiogenesis. In vitro 
studies measuring VEGF concentrations in the supernatant of cells were largely 
inconclusive. Preliminary studies done by members in my lab were able to show 
significant reduction in the VEGF levels of cells treated with EphA2-targeting siRNA, 
but I was unable to repeat this experiment to achieve the same level of significance 
(Figure 19). Furthermore, qRT-PCR analysis revealed no significant change in VEGF 
mRNA levels in MDA-MB-231 Luc and BT549 cells that had stably reduced levels of 
EphA2 in comparison to the EphA2 expressing cells. However, CD31 staining of tumor 
tissue sections of the mice with MDA-MB-231 Luc LV3 mammary fat pad tumors 
revealed a significant decrease in the microvessel density compared to the control tumors 
that were also stained for CD31 (Figure 11). The conclusion to be drawn from this is that 
EphA2 may have an effect on the angiogenic capability of tumors, but it can not be 
assessed in vitro by way of VEGF analysis. The tumor environment in vivo is much 
different from the conditions in cell culture and this may be the cause of the seemingly 
contradictory data. EphA2’s role in angiogenesis may not be direct and may involve 
signaling through other pathways such that simply reducing EphA2 levels would not be 
sufficient to see a significant decrease in VEGF. Studies done in ovarian cancer show that 
EphA2 overexpression highly correlated with angiogenesis in vivo (66). This relationship 
was not as clear in the metastatic breast cancer model, but that does not mean that EphA2 
does not play a role in this process in breast cancer, rather, it requires further 
investigation.   
 In vivo investigation into the ability of stably reduced EphA2 breast cancer cells 
to develop metastases revealed that they are not as efficient at establishing lung 
metastases as their EphA2 overexpressing counterparts (Figure 12). These data suggest 
that not only is EphA2 important for breast cancer cell migration away from the primary 
tumor and into circulation, but it is also important in the ability of these circulating tumor 
cells to successfully establish secondary tumors elsewhere in the body. As previously 
discussed, EphA2 is known for its expression in late stage, aggressive breast cancers and 
these data further implicate that this overexpression is one of the mechanisms that gives 
breast cancer cells increased metastatic capabilities during breast cancer progression. 
Furthermore, tumor establishment using metastatic breast cancer cell lines with shRNA-
mediated EphA2 reduction revealed that mammary fat pad tumors with reduced EphA2 
expression showed decreased tumor growth (Figure 9). This trend was first shown using 
the MDA-MB-231 Luc stable cell lines and this result was repeated in a second 
experiment. Athymic female nude mice were also injected in the mammary fat pad with 
the BT549 stable cell lines, but tumor growth was not observed in either of the BT549 
cell lines (LVNC nor LV3) suggesting that more cells may need to be injected into the 
mammary fat pads for the cells to establish tumors. Subsequent Ki-67 and cleaved 
caspase 3 staining of the MDA-MB-231 Luc LVNC and LV3 tumor tissue sections 
collected from the above experiment did not reveal any differences in Ki-67 or cleaved 
caspase 3 staining in the LVNC mammary fat pad tumor tissue sections when compared 
to the LV3 mammary fat pad tumor tissue sections. The reason for decreased tumor 
growth in these tumors is not related to a decrease in cellular proliferation or an increase 
in cellular apoptosis, possibly due to the relatively modest growth differences in tumors. 
My results suggested that the EphA2 siRNA delivery to tumors using nanoparticles in the 
absence of chemotherapy was the more effective way to knockdown EphA2 receptor 
expression in established mammary fat pad tumors in vivo (Figure 21). However, this 
knockdown was modest when compared with the DOPC liposomes. The indication is that 
while there was a modest reduction in tumor growth observed after treatment of the 
mammary fat pad tumors with EphA2-targeting nanoparticles, the quantity of siRNA 
delivered was not sufficient to reduce EphA2 levels to the point where tumor growth was 
significantly impaired. It’s important to note that delivery of EphA2 siRNA in DOPC 
liposomes has been shown to be effective in an ovarian cancer model after i.p. 
administration which contrasts with our systemic administration. My results indicate that 
increased doses and/or frequency of siRNA injections might lead to more conclusive 
results. Another consideration is that EphA2 expression is driven through the Ras-MAPK 
pathway and the MDA-MB-231 Luc cells express an activating K-Ras mutation (77). A 
more effective approach to diminishing EphA2 receptor levels in this model system may 
involve targeting the EphA2 gene in addition to the Ras-MAPK pathway.  
 In summation, the data collected from this set of experiments that sought to 
elucidate the effect of EphA2 knockdown in a metastatic breast cancer model in vitro and 
in vivo has revealed that EphA2 does play a role in promoting the metastatic potential of 
breast cancer cells. My work has helped to establish that EphA2 seems to have the same 
function in cancer progression as it does during embryogenesis and mammary branching 
morphogenesis, where it aids in the migratory capability of cells. As much as I would like 
to have been able to propose a model for how EphA2 is functioning in the greater scheme 
of things, my work has been more important in confirming that EphA2 functions in breast 
cancer cells similar to how it functions in other cancer models where the mechanisms 
have already been investigated. Despite this progress, more research should be done to 
better understand the effect of EphA2 receptor depletion in metastatic breast cancer cells 
and tumors. It is possible that although EphA2 does assist in the cellular mechanisms that 
promote metastasis, therapeutically targeting it for the treatment of metastatic breast 
cancer may not confer a sufficient anti-tumoral effect as a single agent. Many molecular 
targeted therapies have been shown to be more effective when combined in standard 
therapies. Despite this, EphA2 is still an important receptor due to its robust expression in 
nearly all metastatic breast cancer cell lines. Since triple-negative breast cancers are 
largely defined by the molecular markers that they lack. Knowing that EphA2’s 
expression is common in these cancers and that it is not highly expressed in other tissues 
makes it a possible molecular target for cytotoxic therapy homing (128, 129). Overall, 
EphA2 is an important receptor tyrosine kinase in metastatic breast cancers and the 
unexplored mechanisms behind its modes of action could potentially have relevant 
biologic and therapeutic significance, some of which has been elucidated by the work 
done for this thesis.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Future Directions 
 
 The role of EphA2 in the metastatic capabilities of metastatic breast cancer cells 
should continue to be investigated in the breast cancer model. EphA2 has been shown to 
be a participant other signaling pathways, such as FAK-mediated cellular interaction with 
the ECM in epithelial prostate cancer cells (60). EphA2’s role in pathways such as these 
has yet to be elucidated and investigation into them may highly contribute to gaining a 
more complete understanding of EphA2’s role not only in breast cancer, but in other 
cancer models as well. Furthermore, as discussed in the summary, it may be that EphA2’s 
unique expression on cancerous epithelial cells is going to be more clinically beneficial 
than attempting to hinder the downstream signaling actions that result from EphA2 
overexpression. For example, using the expression of EphA2 as a tumor homing 
mechanism for cytotoxic therapy against metastatic breast cancer might be worth 
exploring in future studies.   
 On a larger scale, the Eph receptors in general have been the target of drug 
developers (130). EphA2 has specifically been the target of drug companies like 
MedImmune which had an anti-EphA2 antibody program, but unfortunately, this project 
was discontinued for unspecified reasons after its acquisition by Astra-Zeneca in 2008 
(130). Furthermore, Pfizer has a preclinical study of an anti-EphA2 tyrosine kinase 
inhibitor that is still ongoing (130). The attention given to EphA2 by drug companies 
signifies that it is an important potential therapeutic target not only for breast cancer 
patients, but for other cancer patients as well. However, development of anti-EphA2 
therapies still has a long ways to go and it is very possible that multiple anti-Eph 
therapies will be needed in order to inhibit the tumor promoting effects of this receptor 
tyrosine kinase family.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
  
 EphA2 is overexpressed in the triple-negative, basal subtype of breast cancers and 
these breast cancers are highly aggressive and metastatic. EphA2 is a participant in the 
migratory ability of breast cancer cells, giving them increased metastatic ability. 
Furthermore, it appears that reduced levels of EphA2 causes a decrease in the MVD of 
mammary fat pad tumors, but the mechanism behind this observation is still unclear. 
Additionally, reduced levels of EphA2 were found to correlate with decreased tumor 
growth in vivo both after treatment of established mammary fat tumors with nanoparticles 
containing EphA2 siRNA, and also in mammary fat pad tumors that were established 
using EphA2-reduced breast cancer cells. While there is still much investigation that 
needs to be done, this work establishes that EphA2 is important in promoting the 
characteristics that allow breast cancer cells to metastasize.  
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